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Abstract
B cell depleting therapies have been effective in the treatment of Multiple Sclerosis (MS), yet to
date little is known about how B cells promote disease pathogenesis. B cells can be found invading
the meninges around the brain and spinal cord in MS, where they cluster in association with T
cells. These meningeal B cells clusters are often adjacent to demyelinating lesions suggesting this
may be a site where B cells are exerting their pathogenic effects. The purpose of this thesis was to
understand the contribution of meningeal B cells to central nervous system (CNS) autoimmunity,
by characterizing their phenotype and determining their susceptibility to B cell depletion. Using
an animal model of MS, immunofluorescence analysis, flow cytometry, or single-cell sequencing
analysis was used to analyze B cells within the inflamed CNS. Interestingly, while anti-myelin T
cells were readily identified in the inflamed CNS, anti-myelin B cells were excluded from this site.
Non-specific B cells within the CNS were phenotypically unique from naïve B cells, exhibiting a
non-classical activation status. Following treatment with anti-CD20, B cells were rapidly depleted
in peripheral tissues such as the blood, lymph node and spleen, while depletion in the CNS was
delayed. Following treatment there was minimal evidence that anti-CD20 accessed meningeal B
cells directly, but rather that depletion was indirect and the result of ongoing turnover of the
meningeal population and elimination of the peripheral pool from which it is sustained. Depleting
B cells from the CNS resulted in significantly less demyelination and T cell accumulation within
meningeal clusters. This suggests that B cells may be required to help with T cell reactivation
within the meninges, and that depletion of B cells over time prevents ongoing local pathology.
Collectively, this thesis elucidates the phenotype of B cells within the inflamed CNS of anti-myelin
autoimmunity, supporting a role for their involvement in disease pathogenesis. By selectively
targeting pathogenic populations of B cells this will help minimize the adverse effects that exist
with current complete B cell depletion therapies.
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Summary for Lay Audience
B cells, an important cell of the immune system, are the targets of some of the most effective
therapies currently used to treat multiple sclerosis (MS). Despite the success these therapies have
in treating patients with MS, the removal of B cells may have negative effects over time such as a
weakened immune response to fighting infections. These therapies confirm that B cells are
involved in MS, yet we still do not understand how B cells are driving disease. Interestingly, B
cells can be found gathering into large clusters in the meninges, a protective covering of the brain
and spinal cord, next to areas where damage has occurred. In this thesis I used animal models of
MS to determine how B cells found within the spinal cord contribute to disease, and whether they
can be targeted for removal by current B cell targeting therapies. I found that B cells located next
to damaged parts of the spinal cord are unable to recognize myelin antigens, the main target in
MS. Our findings suggest these B cells are interacting with other immune cells in the damaged
spinal cord to further intensify the immune response. Finally, using a mouse version of B cell
targeting therapy used in humans, I revealed that B cells in the spinal cord are not being targeted
for removal by treatment, since the drug was not capable of crossing into the brain and spinal cord.
However, by removing B cells in the periphery, B cells in the spinal cord were able to slowly be
reduced as their replacement over time was stopped. This removal of B cells in the spinal cord
reduced the damage that occurred over the course of disease. My thesis provides a new
understanding of the damaging role of B cells in MS. Future work to characterize these B cells
will allow us to identify specific targets for new MS therapies.
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1

Introduction

Our immune system protects us from foreign invaders, such as viruses, bacteria, and
parasites, which can infect us and cause harm. Unfortunately, sometimes our immune
system makes a mistake and instead of protecting us from foreign invaders it mounts an
immune response against ourselves. When this aberrant immune response occurs, the
individual can be left with a chronic autoimmune disease. Multiple sclerosis (MS) is a
chronic autoimmune disease of the brain and spinal cord (the central nervous system –
CNS), that is characterized by demyelination and inflammation resulting in neurological
deficits over time. T cells have long been thought to be the primary drivers of the
autoimmune response; however, the recent success of B cell depleting therapies (1–6)
confirms the role of B cells as critical players in this disease. Relative to T cells, much less
is known about basic B cell biology and even less is known about how these cells contribute
to MS. It is likely that depending on their antigen specificity, location within the body, and
effector phenotype (regulatory vs pathogenic), different subsets of B cells may contribute
to pathogenesis utilizing distinct effector mechanisms. This highlights how essential it is
to understand exactly how these mechanisms work and where they occur. Furthermore, it
is unknown whether B cell depleting therapies universally effect all compartments of B
cells, or if only specific populations are targeted. By addressing these uncertainties, we
may then be able to move beyond trying to treat the disease with broadly depleting
therapies and instead create more targeted and effective treatments with the advantage of
having fewer adverse effects.

1.1 Multiple sclerosis overview
Multiple sclerosis is a complex disease that, despite being first described in 1868 by French
neurologist Charcot (7), still has no known etiology. Over the years, researchers have
identified genetic, environmental and infectious agents that are all involved one way or
another in causing MS. In this section, I will briefly describe the mechanisms thought to
contribute to susceptibility to MS, as well as the clinical manifestation of this disease.
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1.1.1 MS susceptibility: genetics
The current view is that MS develops in genetically susceptible individuals in response to
the right environmental triggers. Studies looking at the familial recurrence rate of MS show
the odds of developing the disease are higher in closely related family members, with no
evidence of genetic transmissibility (8, 9). Genome wide association studies have been
used to identify allelic risk variants among individuals with MS. Consistent with the idea
that this disease is the result of an autoimmune response, the strongest association linked
to MS susceptibility comes from human leukocyte antigen (HLA) class II alleles, located
within the major histocompatibility complex (MHC) region (10–12). MHC class II is
expressed on the surface of antigen presenting cells (APCs) and is essential for the
activation of CD4+ T cells. When looking at non-MHC alleles, the most recent international
genome wide association study found 200 risk variants associated to MS susceptibility
(13). This included genes involved in both the adaptive and innate immune system,
implicating cytokine and chemokine pathways, co-stimulatory molecules, adhesion
molecules, signaling pathways and transcription factors. Nevertheless, these risk variants
only account for a modest association, suggesting additional factors must be accounting
for disease susceptibility.

1.1.2 MS susceptibility: environmental factors
Several environmental factors have also been implicated in MS susceptibility. First, the
odds of developing the disease increase the further away you move from the equator,
suggesting that vitamin D deficiency is associated with MS (14). Indeed, when looking at
patients who have MS, those with lower levels of vitamin D were more likely to develop
new brain lesions observed through magnetic resonance imaging [MRI (15)]. Second,
studies looking at environmental exposure to passive tobacco smoke have also shown an
association with increased risks of developing MS (16, 17). Third, infections as a young
adult with Epstein-Barr virus (EBV) increases the risk of developing MS (18), with
incidence being reduced in EBV seronegative individuals (19–21). This finding is
attributed to various factors including molecular mimicry of an EBV DNA polymerase
peptide, EBV627-647 to a self-protein with four DRB1 T cell receptor (TCR) peptide contacts
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identical for the immunodominant epitope of myelin basic protein (MBP) amino acids 8599 (22–24), which is a major myelin antigen. This is further supported by the finding that
B cells infected with EBV accumulate in brain lesions (25, 26). Finally, diet and the gut
microbiota have also been proposed as a risk factor contributing to MS (27, 28), as an
increased body mass index (29, 30) and numerous microbial infections have been
associated with this disease (31, 32).

1.1.3 Diagnosis and clinical manifestation
The complexity of MS is heightened by the heterogeneity of the disease in terms of the
onset, clinical manifestations, and severity experienced by individuals. The key to
determining if a patient is presenting with features of MS is to be able to demonstrate a
dissemination in time and space, whereby new lesions are observed both over time and in
distinct anatomical locations within the CNS (33). To do this, MRI techniques are used to
identify lesions in the brain and spinal cord (34), lumbar punctures identify the presence of
intrathecal immunoglobulin (Ig) synthesis [predominately IgG, although IgM, IgD and IgA
have also been observed (35)] within the cerebral spinal fluid (CSF) referred to as
oligoclonal bands (OCB) (36), and evoked potential tests are used to measure nerve
responses to stimulation (37). The most frequently experienced symptoms of MS include
motor impairment, vision loss, sensory deficiencies (tingling, numbness), spasticity,
cognitive dysfunction, depression and fatigue (38).
Clinically definite MS is broadly characterized into three distinct subtypes based on initial
clinical presentations and disease progression over time. Typically, before being diagnosed
with MS, patients may exhibit a clinically isolated syndrome (CIS), whereby inflammation
and demyelination in the CNS leads to neurological deficits that last for a minimum of 24
hours, followed by a complete or partial recovery (33). CIS patients may go on to develop
clinically definite MS if an MRI identifies new or existing brain lesions, or CSF OCB are
observed. Relapsing-remitting MS (RRMS) is the most common form of MS that occurs
in 85% of cases (39). It is characterized by clinical episodes of disease worsening with
active inflammatory demyelinating lesions forming in the CNS, followed by partial or total
recovery. Over time, a majority of RRMS patients develop a secondary progressive form
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of the disease (SPMS), where it is thought that ongoing local inflammation occurs within
the CNS leading to neurodegeneration, oligodendrocyte loss and progressive disability (40,
41). Alternatively, 15% of individuals will develop primary progressive MS (PPMS),
characterized by continuous disease progression from the onset (33). PPMS, like SPMS,
results in fewer newly active inflammatory demyelinating lesions, and instead is
characterized by having chronic active or slowly expanding lesions with occasional
lymphoid neogenesis observed (41–43). PPMS is typically diagnosed in older populations,
with frequent lesion formation in the spinal cord (44).
Various additional demyelinating disorders exist that should not be confused with MS.
Devic’s disease, otherwise known as neuromyelitis optica (NMO), is a relapsing disease
that affects the optic nerve and spinal cord. This disease is differentiated from MS by
minimal brain involvement or OCB and instead results in continuous spinal cord lesions
and the presence of serum aquaporin-4 (AQP4) antibodies (45, 46). In contrast to NMO,
myelin oligodendrocyte glycoprotein (MOG) antibody disease is a monophasic or
relapsing neurological disorder with a better prognosis for patients. Individuals affected
with this disease frequently present with serum MOG-autoantibodies while the presence of
OCB is uncommon (47).

1.2 CNS pathology in MS
The brain and spinal cord historically were considered to be immune privileged sites that
are highly restrictive in the migration of cells and molecules (48). The CNS is surrounded
by the meninges, a highly vascularized tissue, made up of three layers being the outermost
dura, arachnoid, and inner pia mater. The arachnoid and pia mater form the leptomeninges,
and the subarachnoid space between them is where CSF circulates (49). The inner pia mater
continuously envelops the brain and spinal cord parenchyma, following all the gyri and
sulci (50). The pia mater also lines the endothelium of smaller arteries and veins that can
penetrate into the parenchyma (51, 52), thereby separating the perivascular space from the
subarachnoid space (49).
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Within the CNS there are three major barriers that regulate the transport of molecules from
the peripheral blood: the blood brain barrier (BBB), blood-leptomeningeal barrier (BLMB)
and the blood-CSF barrier (BCSFB). The BBB is best characterized, having multicellular
components; endothelial cells that line the BBB are sealed by tight junctions and covered
by pericytes which together secrete the extracellular matrix of the inner vascular basement
membrane (53). The CSF draining perivascular space encompasses the vascular basement
membrane with perivascular macrophage, an APC, surveying the area. Finally, the border
ends at the glia limitans, comprised of the parenchymal basement membrane (created by
astrocytes) and astrocyte endfeet (54). In contrast to this multicellular BBB, the BLMB is
unicellular with endothelial cells only sealed by tight junctions. Leptomeningeal
macrophages survey the subarachnoid space for any infiltrating cells. Finally, the BCSFB
is the tight junction sealed epithelial layer of the choroid plexuses (produces CSF) that
separates fenestrated capillaries within the choroid plexus from the CSF (55). Epiplexus
cells, a type of APC, line the endothelial cells, patrolling for any migration through this
area. Analysis of adhesion molecules of these various endothelial surfaces revealed the
BLMB as the easiest barrier to breach as endothelial cells constitutively express P-selectin
(56). Together these various barriers highly regulate the migration of molecules and
immune cells in and out of the CNS.
Since MS is thought to be the result of an autoimmune response initiated against the myelin
sheath surrounding the axons in the brain and spinal cord, leukocyte infiltration must occur
in order to initiate the disease. Until recently, the most common CNS pathology in MS was
white matter lesions. Active focal white matter lesions characterized by an overall
inflammatory phenotype with significant BBB disruption, lymphocyte infiltration, and
complement deposition (57), have frequently been observed in early phases of the disease
(CIS and RRMS), while largely being absent in progressive forms. Instead, in progressive
MS it is more common to observe slowly expanding, chronic lesions of the white matter,
with a low degree of demyelination and no BBB disruption (58). With the advent of more
sensitive MRI methodologies it became clear that grey matter lesions, also known as
cortical lesions, are also a recognized feature in MS pathology (59, 60). Typically, grey
matter lesions are associated with more progressive forms of the disease (61), with lesions
that are broadly characterized as cortical, intracortical, or subpial (62). Subpial lesions are
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often associated with meningeal inflammation that can be either diffuse or densely packed
with B and T cells that can occasionally be observed forming into ectopic B cell follicles
(discussed in more detail in section 1.2.2) (63). This meningeal inflammation is primarily
observed in SPMS (63–68) and PPMS (42, 43, 69), and is correlated with substantial
cortical pathology (42, 65–68). However, it is becoming increasingly accepted that cortical
demyelination and meningeal inflammation can also be observed in early MS (70, 71).
Overall, infiltrating cells of MS lesions include CD4 and CD8 T cells, macrophage,
microglia (CNS resident macrophage), dendritic cells (63, 72, 73), and B cells (74).
Invading immune cells are able to mediate demyelination via CD8+ cytotoxic T cell
responses, complement dependent cell cytotoxicity (CDC), antibody dependent cell
cytotoxicity (ADCC), and the release of toxic mediators such as reactive oxygen species.

1.2.1 T cells in MS
It is widely proposed that MS is initiated by the activation of autoreactive T cells in the
periphery in response to myelin antigens (1) or through molecular mimicry (20, 22). CNSdraining cervical lymph nodes have been implicated as the site where immune cells are
activated due to their abundance of myelin antigens (75, 76). The recruitment mechanisms
T cells use to gain access to the CNS have been best characterized using rodent models of
MS (more details in section 1.3). Under healthy conditions, low levels of activated (but not
naïve) CD4+ T cells, regardless of their specificity, cross the various BBBs using the
adhesion molecules 4-integrin and P-selectin glycoprotein ligand (PSGL-1) (77–79).
Because of the constitutive expression of P-selectin on the BLMB, T cell migration across
this barrier is more efficient and frequently observed (80). Once in the CNS, CD4+ T cells
must then be reactivated by local APC, such as perivascular macrophages or dendritic cells
(DC), in order to be retained within the perivascular space and parenchyma below (81–86).
This reactivation subsequently leads to increased BBB permeability as T cells proliferate
and secrete proinflammatory cytokines and chemokines, further driving immune cell
recruitment to the CNS resulting in an inflammatory lesion (79, 87). Activated CD8+ T
cells like CD4+ T cells have also been shown to utilize 4-integrin to cross the BBB (88);
however, it is unknown whether reactivation is required for their retention. Once CNS
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inflammation occurs, 4-integrin, endothelial P- and E-selectins and a wide array of
inflammatory chemokines are responsible for T cell access to the CNS (89–93).
Despite genome wide association studies frequently linking susceptibility of MS to MHC
class II (10, 13), histological evaluation of MS lesions reveals CD4+ T cells as a minor
population of immune cell infiltrates (69). Nevertheless, CD4+ T cells infiltrating the CNS
are observed more frequently in the perivascular spaces and meninges (68, 94–96). It has
been proposed that CD4+ T cells – in addition to contributing to the initiation of disease in
the periphery (87) – contribute to ongoing disease pathogenesis through numerous
mechanisms, including cytokine-mediated toxicity, ligand-mediated apoptosis, reactive
oxygen species, and matrix metalloproteinases (97). Furthermore, CSF and peripheral
blood Th1 T cells from SPMS patients have been shown to secrete granzyme and perforin
in response to anti-CD3 and anti-CD28 T cell activation (98). In contrast to CD4+ T cells,
CD8+ T cells are predominately observed in the lesions of MS patients (68, 69, 94, 99),
phenotypically characterized containing granzyme B cytoplasmic granules indicating
cytotoxic differentiation (69, 88, 100, 101). HLA class I molecules are constitutively
expressed on BBB endothelial cells and perivascular macrophage, and its expression on
oligodendrocytes, astrocytes and neurons can be found in active inflammatory lesions
within the CNS (102), thereby creating a means for antigen specific CD8+ T cell mediated
cytotoxicity. In fact, CD8 T cell infiltration in lesions has been shown to correlate with
axonal injury (103), supporting the immunopathogenic capabilities of this cell. CD8+ T
cells have also been observed inducing cytokine mediated toxicity (104, 105) and FasLmediated cell death (106).

1.2.2 B cells in MS
For years, the contribution of B cells to MS has been solely attributed to the identification
of antibodies in the CSF seen as OCB (33, 107). Indeed, deposition of antibodies can be
seen within some MS lesions (108–111) and the presence of OCB has been shown to
correlate to more severe disease (112–114), suggesting antibodies are involved in disease
pathogenesis. Interestingly, OCB are unique to the CSF and not found in peripheral blood,
with further investigation revealing that plasma cells in the CSF are the main contributor
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to this polyclonal B cell humoral response (115). Nevertheless, when characterizing the
target of Igs produced in the CSF, consistent results are rarely observed, with some MS
patients purified antibodies from OCB targeting cellular debris (116). When analyzing the
target antigen of CSF B cells as a means to identify OCB Ig specificity, such specificity
towards lipids (117–119), myelin proteins (120–124), bacterial antigens such as Chlamydia
pneumoniae (125), and viral antigens (126–129) could all be identified at varying
frequencies. A study by O’Connor et al., found IgG purified from CNS parenchyma had
strong specificity for MOG in 50% (7/14) of cases while CSF and serum IgG did not (130).
Interestingly, recent developments have even been made to further delineate distinct
demyelinating diseases based on antibody specificity within peripheral blood, with AQP4
being a strong indicator of NMO (46) and anti-MOG antibodies suggestive of MOG
antibody disease (47). Nevertheless, this heterogeneity of Ig specificities and inability to
frequently recapitulate the presence of myelin-autoantibody reflects the complexity of MS
as a disease and the varying role autoantibodies may play.
Clusters of B cells have also been observed in the meninges of patients with SPMS (63–
68) and PPMS (42, 43, 69). These clusters of B cells are often found next to demyelinating
lesions with severe cortical pathology and often result in an aggressive clinical course (42,
65–68), suggesting that they may be important anatomical sites from which B cells are
exerting their pathogenic effects. Certain studies investigating these B cell clusters
sometimes term them as ectopic B cell follicles (63), meaning they become organized
similar to secondary lymphoid tissue. Based on this preconception, most attention has been
focused on looking for events as they occur in secondary lymphoid tissue like germinal
centers (GCs). Indeed, when analyzing sections of post-mortem human brain and spinal
cords, some groups are able to demonstrate that CD20+ B cells, CD138+ plasma cells,
CD35+ follicular dendritic cells (FDC), and Ki67+ proliferating CD20+ B cells can be found
within meningeal B cell clusters (64–67). Occasionally they can also be seen containing
activation-induced cytidine deaminase, the enzyme responsible for somatic hypermutation,
activated caspase-3, which induces apoptosis of low affinity B cell receptors (BCRs), and
Bcl-2, which promotes survival of GC B cells (63). Another group was also able to identify
CD38hiCD77+Bcl2- centroblasts and CD38hiCD77-Bcl2- centrocytes in the CSF of patients
with MS, indicative of a GC secondary lymphoid follicle (131). The human memory B cell
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marker CD27 has also been identified in these meningeal B cell aggregates, representing a
majority of the B cells present in this location (80% – 98%) (25, 66). Studies looking at the
clonal relationship of B cells within the CSF and CNS compartments reveal shared Igheavy (132–136) and light chain variable sequences (36, 137), with evidence of clonal
expansion, somatic hypermutation, and variable heavy gene segment bias (Vh4) (138–
141), which these studies suggest is representative of a localized antigen-driven B cell
response. However, longitudinal studies (142), as well as paired tissue Ig receptor
sequencing (135, 143–145) have also demonstrated frequent input from peripheral B cells.
Nevertheless, the antigen(s) that drive this immune response have yet to be identified, as
antibodies generated from clonally expanded B cells from MS brain tissues did not bind to
autoantigens that were unique to MS, while non-MS-derived antibodies had similar binding
specificity (146). Based on these human post-mortem CNS findings it has been suggested
that meningeal B cell clusters may be where B cells are being locally amplified in the CNS,
differentiating and contributing to the inflammatory response found in surrounding tissues
(74, 147). Nevertheless, on a closer analysis of the literature it is quite clear that these
events are rare and instead diffuse meningeal inflammation or disorganized meningeal B
cell clusters are a more frequent phenomenon (42, 43, 65–69). Although this provides
important information on aspects of disease pathologies from time-points much further in
disease progression, human experiments fall short in their ability to understand how the
initiation of disease transpires. This draws attention to the many important questions that
still remain unclear, such as what these meningeal B cells are and whether they are involved
in disease pathogenesis.

1.2.3 B cell targeting therapies in MS
Although the availability of treatment options have increased over the years, there is still
no cure and most effective therapies are broadly immunomodulatory, targeting a wide
range of undefined mechanisms (148). First generation therapies including the cytokine 
interferon and synthetic protein glatiramer acetate were described as functioning by
modulating the T cell response of the disease (149, 150). The mechanistic understanding
of T cell recruitment to the inflamed CNS was key in establishing one of the first and most
potent second-generation therapies in RRMS, natalizumab (anti-4-integrin) (151).
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Natalizumab was effective in reducing relapses in RRMS patients, as well as reducing
CD4+ and CD8+ T cell and B cell migration from the peripheral blood to the CSF (152);
however, its use is restricted due to the increased risk of developing progressive multifocal
leukoencephalopathy, an opportunistic brain infection resulting from reemergence of John
Cunningham virus (153). In contrast, therapeutic strategies that directly target CD4+ T
cells, have been ineffective in treating patients with MS despite effective depletion of
peripheral CD4+ T cells (154).
More current therapies tend to be more aggressive, depleting entire branches of the immune
response. This includes anti-CD20 monoclonal antibody therapies such as rituximab
(chimeric human/mouse IgG1), ocrelizumab (humanized IgG1), and ofatumumab (fully
human IgG1), which have been effective in treating patients with RRMS (1–3) and more
importantly progressive forms of MS (5, 155) which currently have no other FDA approved
therapeutic options. CD20 is a transmembrane calcium channel implicated in B cell
activation, proliferation and differentiation (156), and is expressed by pre-B, immature,
mature, and memory B cells, but not pro-B or antibody secreting cells (ASC). Indeed,
following treatment with anti-CD20, clinical trials have confirmed that while CSF B cells
are reduced, there is no impact on the level of antibodies present (2, 157, 158). Therefore,
while autoantibodies may be key in disease pathogenesis in some MS patients, NMO, and
MOG-antibody disorders, it must not be the only mechanism B cells are using to contribute
to disease pathogenesis in MS.
Besides the ability to mature into antibody producing plasma cells, B cells are also capable
of producing pro-inflammatory (159, 160) or regulatory cytokines (161, 162), as well as
being able to act as APCs (64, 163–167). These in turn could be alternative mechanism(s)
B cells are employing that further aid in disease pathogenesis. Studies looking at the
peripheral blood following anti-CD20 treatment highlight some of these roles B cells play
in disease pathogenesis as peripheral blood B cells stimulated ex vivo have been shown to
produce decreased levels of IL-6 (159) and granulocyte macrophage colony stimulating
factor (GM-CSF) (160) following B cell depletion. While anti-CD20 B cell depleting
therapies have been effective in limiting new and existing brain lesions, clinical relapses
and disability progression (1–6, 168–170), they still, however, are broadly
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immunosuppressive as they non-specifically target immune cell populations and have been
shown to increase the risk of opportunistic infections, autoimmune disorders and cancer
(148, 171). Furthermore, it is unclear whether the reduction of B cells in the CSF is due to
the direct entry of anti-CD20 into the CNS or due to the indirect depletion of the trafficking
pool of B cells that enter from the periphery into the CNS.
Despite the clinical success anti-CD20 therapies have on MS, attempts to deplete B cells
via alternative mechanisms have also been investigated with varying results. Atacicept, a
fully humanized recombinant fusion protein containing the extracellular ligand-binding
portion of the human TACI receptor linked to a recombinant Fc domain of human IgG
(TACI-Fc), was terminated early due to exacerbations in disease (172). TACI-Fc is a
soluble recombinant cytokine receptor similar to TACI that results in B cell depletion by
blocking the effect of B cell activating factor (BAFF) and a proliferation-inducing ligand
(APRIL), two key cytokines from the tumor necrosis factor (TNF) family that result in B
cell proliferation, maturation and survival (173, 174). The conflicting results of TACI-Fc
to anti-CD20 therapies may be attributed to the broader effects of blocking BAFF and
APRIL in comparison to depleting CD20 expressing cells, as monocytes, dendritic cells,
neutrophils and T cells have also been shown to express BAFF receptors (175, 176).
Importantly, TACI-Fc depletes antibody producing plasma cells in addition to B cells,
suggesting a protective function B cells may be providing in CNS autoimmunity. In
contrast to atacicept, inebilizumab, an anti-CD19 B cell depleting therapy which targets a
broader range of B cells, including pro-B cells and Ig-producing plasmablasts, was
successful in reducing new gadolinium-enhancing lesions in RRMS in a recent phase I
clinical trial (177). Interestingly, a clinical trial of inebilizumab treatment in NMO, which
is known to result in autoantibodies, was halted early due to a clear therapeutic benefit
(178); however, whether this was due to a reduction in anti-AQP4 antibodies remains to be
addressed. Finally, Evobrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor which inhibits
BCR signaling (179) is being tested in RRMS patients with promising results (180).
Overall, the therapeutic success of anti-CD20 B cell depleting therapies confirms B cells
contribute to the pathogenesis of MS, although further research is required to understand
the various B cell populations involved in disease pathogenesis in order to allow for more
selective targeting of pathogenic populations and maintenance of regulatory B cell pools.
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1.3 Animal models of MS: EAE and lessons we have learned
Animal models are essential and integral components to human disease research enabling
the ability to understand the disease from various different stages, genetic modifications,
and manipulations (181). Serendipitously discovered, experimental autoimmune
encephalomyelitis (EAE), was first observed in humans immunized with rabies vaccines
that contained crude rabbit spinal cord extracts (182), resulting in an anti-myelin
inflammatory response with symptoms of paralysis and CNS inflammation (183–185).
Adapted for research purposes, the most commonly used animal model for human MS is
usually represented by the use of mouse models of EAE, as the reagents and targeted genedeletion models are abundant in this species. EAE can be induced by various different
mechanisms, and depending on how it is induced and which strain of mouse is used –
C57BL/6 mice are most common, followed by SJL/J and Biozzi antibody high mice – can
have major implications on the role B cells play in disease pathogenesis. Nonetheless, EAE
recapitulates several symptoms of MS including limb weakness/paralysis, leukocyte
infiltration and inflammation in the CNS typically restricted to the spinal cord in most
models of EAE (186). Less common symptoms of EAE include altered gait and ataxia,
which result when brain inflammation occurs (187, 188). Furthermore, EAE is influenced
by the sex, age, season and housing facilities (189, 190). Here, I will briefly describe the
initiation of immune responses and various models of EAE that taught us about the role B
cells play in anti-myelin autoimmunity.

1.3.1 Initiation of immune responses
Before being able to understand the various models of EAE, a basic understanding of how
antigen-specific immune responses are initiated is required. Typically, immune responses
occur in secondary lymphoid organs (SLO) such as the lymph nodes and spleen. Cells of
the adaptive immune system, including T and B cells, reside in these tissues and are
constantly surveying for antigen that they recognize and can mount an immune response
against. Naïve CD4 T cells are incapable of recognizing antigen on their own and instead
require help from a mature DC acting as an APC to present epitopes from antigens to the
TCR via MHC class II complexes. Similarly, naïve CD8 T cells require the aid of APCs,
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though in the context of TCR-MHC class I receptor signaling. In contrast, B cells are able
to bind directly to protein antigens via their BCR; however, additional help from CD4+ T
follicular helper cells (Tfh) is required. B cells, like DCs and macrophage, are a type of
APC that expresses MHC class II. Using their BCR they can endocytose antigen,
processing it into short peptides that can then be loaded onto their MHC class II for
presentation to T cells. This epitope loaded MHC class II interaction with Tfh cells, with
the addition of co-stimulatory receptors, allows for a cognate interaction between B and T
cells that recognize the same antigen leading to a GC response. GCs allow for B cells to
undergo extensive clonal expansion, somatic hypermutation and class switch
recombination, with an end product of high-affinity memory B cells and plasma cells.

1.3.2 Peptide and passive transfer EAE models
For the last two decades, peptide models of EAE have dominated the field as they can be
synthesized efficiently at a relatively low cost. The most common peptide model of EAE
is based on the extracellular domain of MOG, MOG35-55 (191). This allowed for effective
characterization of the CD4+ T cell response that occurs in MS as this peptide represented
an immunodominant CD4+ T cell epitope that could be presented to T cells by APCs (192,
193). Using this model of EAE, CD4+ T cells are cast as the star of immunopathogenesis,
as immunization bypasses antigen processing and presentation by B cells, diminishing the
role B cells play in immune responses. Moreover, if B cells are depleted prior to MOG3555

disease induction, or disease is induced in B cell-deficient mice, this results in similar

and in some cases more severe disease (161, 162, 194, 195), which is associated with a
reduction in IL-10 producing regulatory B cells (161, 162). Overall, this model sheds light
on the regulatory roles of B cells in MS but diminished their contributions to disease
pathogenesis.
Passive EAE, which results from the adoptive transfer of pre-primed myelin reactive T
cells into naïve recipient mice, has demonstrated that both Th1 and Th17 T cells play an
important role in EAE pathogenesis (196, 197). An integral study done by Jager and
colleagues revealed that different effector T cell subsets can alter pathologies and patterns
of immune cell infiltration (198). Indeed, it has been shown that IL-17 and IL-22 cytokine
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production, in addition to lymphotoxin  expression and podoplanin on the cell surface
of Th17 cells, is important for the formation of ectopic B cells follicles in EAE (199, 200).
Passive transfer of myelin reactive CD8 T cells into naïve recipient mice is also capable of
inducing EAE (188, 201); however, how B cells play a role in this model of EAE is not
well characterized.

1.3.3 Protein models of EAE
The role of B cells in EAE was deemed dispensable with animal models frequently utilizing
the classical MOG35-55 induced EAE in C57Bl/6 mice. However, immunization with larger
protein antigens, which allow for the incorporation of tertiary structure, permit the
incorporation of B cells and additional lymphocytes creating a more complex interplay of
immune cell involvement. Our lab has shown that B cells activated by MOG35-55 induced
EAE do not recognize MOG protein (202), limiting the use of this model to characterize B
cell involvement in CNS autoimmunity. Protein induced models of EAE have therefore
become more common with the best characterized model being based on rat or human
MOG. Rat MOG1-125 (rMOG), which contains the encephalitogenic CD4+ T cell epitope
MOG35-55, induces EAE that is not dependent on B cells (203). In contrast, an important
distinction was made when immunization of C57Bl/6 mice with human MOG1-120 (hMOG)
protein induced B cell dependent disease (194, 203). This protein differs from rMOG at
several sites, however a key substitution from serine to proline at position 42, results in a
weak encephalitogenic CD4+ T cell epitope (204). In B cell deficient mice, hMOG
immunized mice were resistant to EAE, although this was not due to B cells being required
to act as APCs (203), but was dependent on antibody production (205–207). Alternative
protein models of EAE also exist, such as MP4, a fusion protein of MBP (21.5-kDa isoform
of human MBP) and proteolipid protein (PLP [three hydrophilic loops of PLP]), that
induces antibody dependent EAE (208), that also involves CD8 T cells (209), and the
formation of meningeal B cell clusters (210).
Nevertheless, at its core MS is an autoimmune response to self-antigen and while rMOG,
hMOG and MP4 allow for a more complex immune response than peptide induced or
passive EAE, they are not naturally occurring proteins in the mouse CNS. Therefore, our
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lab generated a new fusion protein (mMOGtag) based on the mouse MOG1-125 extracellular
domain (202, 211), that contains the immunodominant CD4+ T cell epitope (MOG35-55)
like rMOG. Overall, our lab has demonstrated that immunization with mMOGtag results in
induction of a GC response that incorporates B cell recognition of MOG, unlike the
response initiated by MOG35-55 peptide (202). In addition, the disease featured extensive
white matter infiltration by CD4+ T cells, demyelination, and regular formation of B cell
clusters within the meninges making it an attractive model to investigate how these
structures are involved in CNS autoimmunity.

1.3.4 Spontaneous models of EAE
While inducible models of EAE allow for consistent and reliable experimental conditions,
it is an artificial autoimmune response that manipulates the initiation of the disease towards
large quantities of antigen and potent adjuvants. In contrast to these models, spontaneous
models of EAE (sEAE) have been developed that are reflective of the spontaneous onset
in MS. Typically, sEAE occurs in mice that have genetically modified lymphocyte
receptors with specificity towards myelin, allowing for enhanced recognition of myelin
antigens. For example, TCR transgenic mice, such as SJL mice expressing a transgenic
TCR specific for MOG92-106 (TCR1640), develop sEAE that results in the expansion of
endogenous MOG-reactive B cells and development of autoantibodies specific for native
MOG protein (212). This model of sEAE results in inflammation in the brain and spinal
cord. Alternatively, C57Bl/6 mice expressing a transgenic TCR specific for MOG35-55
(2D2) develop sEAE that occurs at a much lower incidence (4%) (213). Interestingly, if
you cross 2D2 mice with IgHMOG mice (214), expressing a MOG1-125 specific BCR
knockin, the double mutant offspring develop sEAE at a much higher incidence (215, 216),
emphasizing the pathogenic role B cells play in the initiation of this model. In contrast to
TCR1640 sEAE, inflammation in 2D2 IgHMOG mice is confined to the spinal cord and optic
nerve. Nevertheless, both models replicate the formation of meningeal B cell clusters and
are therefore an alternative model that can be used in investigating the role of meningeal B
cell clusters in MS pathology (212, 215–217).

17

Most of our understanding of T and B cell biology in MS has come from what we have
learned from animal models of CNS autoimmunity. The various models of EAE are
heterogeneous in their onset, course and inflammation, which is why each model continues
to be used to account for the many complexities of MS. When trying to understand the role
B cells play within meningeal B cell clusters, utilization of the right model of EAE is
necessary.

1.4 B cell contributions to EAE
By using various animal models of MS, researchers have been able to recapitulate many
aspects of the disease enabling the ability to better characterize potential contributions B
cells may play in disease pathogenesis. In this section, I will describe the B cell
mechanisms that are thought to contribute to anti-myelin CNS autoimmunity.

1.4.1 Meningeal B cell clusters in animal models
Meningeal B cell clusters are a common occurrence in all stages of MS, with better
characterization being performed in progressive phases of the disease (42, 43, 63–70). This
phenomenon can also be recapitulated in certain animal models of CNS autoimmunity,
making them an attractive model to study how these structures are involved in disease
pathogenesis. Nevertheless, just like meningeal B cell clusters in MS patients, these
clusters of B cells in EAE often take on the form of unorganized aggregates of B and T
cells, lacking the phenotypic characteristics of tertiary lymphoid tissue. Indeed, an analysis
by Magliozzi and colleagues revealed the formation of meningeal B cell clusters occurring
in the brain stem and spinal cord of two models of EAE: SJL mice immunized with peptide
PLP139-151, and Biozzi antibody high mice immunized with spinal cord homogenate (218).
These clusters occasionally expressed markers of GC phenotypes such as CXCL13, a
chemokine that drives B cell zone organization, FDCs, and Ki67, a proliferative cell
marker; however, these features were only identified in a small percentage of the clusters
analyzed, and often only one of these phenotypes were observed. In contrast, MP4 induced
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EAE was shown to generate tertiary lymphoid tissue in the meninges and the parenchyma
of C57Bl/6 mice 61% of the time during chronic disease (d30-57 after disease onset) (210).
These clusters were only classified as tertiary lymphoid tissue if there was B and T cell
compartmentalization, high endothelial venules (HEV), and at least one additional
characteristic phenotype such as FDCs, plasma cells, Ki67+ B or T cells, reticulin fibers
and activation-induced cytidine deaminase expression, highlighting that with time, these
clusters can go on to form tertiary lymphoid tissue.
Preliminary analysis characterizing the immune response in 2D2 IgHMOG sEAE mice
revealed profound infiltration in the spinal cord white and grey matter by CD4+ T cells,
demyelination, and formation of large B cell clusters (217). These clusters often lacked
evidence of tertiary lymphoid tissue as there was no evidence of CD138+ plasma cells, little
proliferation in comparison to CD4+ infiltrating T cells, and no evidence of class switching.
Interestingly, when analyzed via flow cytometry, spinal cord B cells did possess an
elevated level of CD80 and a reduced level of CD62L in comparison to lymph node B cells,
suggesting some level of activation had occurred. Moreover, we were able to demonstrate
that disease severity correlated with cluster size, suggesting that while follicular
differentiation may occur with time it is not the minimum requirement for pathogenic
effects to be observed (217), consistent with some human reports (42, 70). While
characterized to a lesser extent, my lab has also shown that mMOGtag induced EAE results
in the development of meningeal B cell clusters (202). However, these clusters were also
apparent in mice immunized with MOG35-55, albeit at a lower frequency, and in mice with
a mutant BCR specific for an irrelevant foreign antigen, suggesting the ability of a B cell
to recognize MOG protein is not a requirement for meningeal cluster formation to occur.
It is important to note that MS is a highly variable disease and that with time these folliclelike structures may result. Still, the models we have combined allow us to address critical
questions regarding the role of meningeal B cell clusters in CNS autoimmunity and their
susceptibility to anti-CD20 B cell depleting therapies.
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1.4.2 Potential pathogenic B cell mechanisms in EAE and MS:
antibody production
In many models of EAE, like MOG35-55, MBP and PLP induced EAE models, production
of autoantibodies is not a major contributor to disease pathogenesis. Nevertheless, some
models of EAE do generate pathogenic autoantibodies, such as hMOG protein induced
EAE in C57Bl/6 mice (203, 205, 206, 219, 220), that can restore disease in B cell deficient
mice (207). In contrast, while pathogenic autoantibodies are produced in MP4 protein
induced EAE in C57BL/6 mice, these antibodies are not pathogenic on their own (208). It
has also been shown that antibody production by IgHMOG B cells allows for concentration
of target myelin antigens allowing for more efficient T cell activation with either MOG3555 or rMOG, resulting

in increased disease incidence and severity, as well as an earlier onset

of clinical symptoms (221). This is supported by work from Kinzel et al., that show that
CNS antigen opsonization by myelin reactive Ab produced by IgHMOG B cells allows for
efficient uptake by myeloid cells via the Fc receptor, allowing for an increased incidence
of sEAE in 2D2 mice (36%, 5/14 mice) supporting the pathogenic capabilities of antibodies
in EAE (222). Indeed, as mentioned in previous sections, high levels of antibodies in CSF,
in the form of OCB (107, 223), is a hallmark feature in MS, and the presence of plasma
cells have been reported within meningeal B cell clusters (43, 64, 65, 69). Although these
features may contribute to pathology in a subpopulation of MS patients and in some animal
models (224), CD20-targeting therapies complicated this notion as plasma cells are not
depleted, nor are antibody levels impacted within a therapeutically relevant timeframe
(225). Therefore, while antibodies may still influence the immune response or contribute
to disease severity, they must not be the primary pathogenic contribution of B cells to
disease.

1.4.3 Potential pathogenic B cell mechanisms in EAE and MS:
cytokine production and toxic factors
Independent of antibody production, B cells can modulate T cell responses through the
production of proinflammatory and regulatory cytokines. Indeed, it has been shown that
the B cells isolated from the peripheral blood of MS patients secrete elevated levels of
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proinflammatory cytokines TNF-, lymphotoxin-, IL-6, and GM-CSF (159, 160, 226,
227), while anti-inflammatory IL-10 producing B cells are reduced in the peripheral blood
of MS patients (228, 229). Furthermore, peripheral blood B cells from RRMS patients, but
not control patients, have been shown to secrete non-Ig, non-cytokine, and noncomplement mediated molecules that are toxic to oligodendrocyte in vitro and results in
apoptosis (230, 231), suggesting B cells could be influencing CNS pathology through this
as of yet unidentified mechanism. Consistent with human studies of MS, animal models of
EAE have also shown that B cells can produce proinflammatory cytokines. B cells from
MOG35-55 induced EAE secrete elevated levels of IL-6 compared to control mice (159),
and selective knock out of IL-6 from B cells results in reduced disease severity and
decreased Th17 responses (165). An important finding in animal models was the
identification that B cells that lack the expression of IL-10, result in more severe disease
in C57Bl/6 mice immunized with MOG35-55 (161). Indeed, since then it has been shown
that ASC are a key source of anti-inflammatory cytokines such as IL-10 and IL-35 (162,
232, 233). This led to the observation that while pathogenic B cells exist in MS, antiinflammatory B cells can also be playing a role in regulating disease pathogenesis.
Supporting this notion was the identification of a rare population of IL-10 producing B10
like B cells in the peripheral blood of MS patients (234). Overall, it is likely that different
populations of B cells contribute differently to CNS autoimmunity, similar to what is seen
with T cells.

1.4.4 Potential pathogenic B cell mechanisms in EAE and MS:
antigen presentation
B cells constitutively express MHC II which allows them to act as APCs, influencing T
cell activation through direct interactions (163, 235). Since B cells specifically take up
antigen that bind to their BCR they, unlike other APCs, present antigen to T cells through
“cognate” interactions, where T and B cells are specific for the same antigen (236). Cognate
interactions are foundational to a GC response (237); therefore, it is almost certain that B
cells must participate in this way during the initiation of the original anti-myelin response
leading to MS. Furthermore, T cells that are strongly reactivated in the CNS are reportedly
capable of increasing the degree of parenchymal inflammation (83), which is dependent on
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the affinity of the TCR for its cognate ligand and the number of myelin-epitope-MHC
complexes available on the surface of APCs, making B cells a probable candidate for
reactivation within meningeal clusters. Indeed, animal models looking at the importance
of B cell APC function in CNS autoimmunity have reported that the presence of MHC II
on B cells is required for disease initiation by hMOG (165). B cells are also capable of
serving as the sole MHC class II expressing APC in passive EAE (166), and when
controlled temporally for their expression of MHC class II can result in rapid disease onset
in comparison to recipient mice with unaltered MHC class II expression (167). As
mentioned previously, sEAE also occurs in a greater proportion of 2D2 mice when crossed
with myelin specific IgHMOG mice (215, 216), highlighting the importance of myelinspecific B and T cells cooperating to induce disease. Furthermore, it has been shown that
2D2 IgHMOG mice that are genetically altered to be unable to secrete antibodies are still
capable of developing sEAE with meningeal B cell clusters (165), emphasizing the critical
role B cells play as APCs in the initiation of EAE independent of antibody production.
Consistent with these animal models of CNS autoimmunity, a recent report by Jelcic et al.,
revealed that memory B cells isolated from the peripheral blood of RRMS patients are
potent inducers of myelin-specific T cells responses (238). Coupled with the observation
that T cell accumulation is reduced in the CSF of patients following Rituximab treatment
(158), this supports a role for B cells in T cell activity within the inflamed CNS.
While B cells have clearly been identified as capable APCs in the peripheral EAE immune
response, their role as APCs within meningeal B cell clusters have been far less
characterized. B cells have been proposed to function as local APCs within the naive CNS,
reactivating newly recruited myelin-specific T cells in passive transfer EAE, as B cells
make up the predominant MHC class II population in the naïve CNS (239). However, the
function of meningeal B cell clusters during chronic EAE remains to be addressed.
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1.5 Rationale and objectives
This thesis aims to characterize B cells within the inflamed CNS in animal models of antimyelin autoimmunity. Based on observations of B cell accumulation in the meninges
observed in human and animal models of MS, I initially hypothesized that myelin-specific
autoimmune B cells infiltrate the CNS and drive local pathology, particularly through
cognate interactions with T cells. Secondly, I hypothesized that anti-CD20 treatment after
chronic EAE is established would reduce meningeal B cells and CNS pathology. To this
end, I designed a series of studies to identify pathogenic populations of B cells, their
anatomical location, and determine their susceptibility to targeted depletion by anti-CD20
B cell depleting therapies.

1.5.1 Rationale for Chapter 3: Activated B cells participating in the
anti-myelin response are excluded from the inflamed central
nervous system in an inducible and spontaneous model of
experimental autoimmune encephalomyelitis
Unlike T cells, B cells have not been well characterized within the context of CNS
autoimmunity. We know B cells can produce proinflammatory or regulatory cytokines and
act as APCs; however, we have yet to identify exactly what these B cells are doing within
the CNS to promote or potentially even mitigate inflammation. To begin to understand how
meningeal B cells contribute to disease, I characterized their specificity and activation
status using two animal models of EAE: mMOGtag induced EAE and 2D2 IgHMOG sEAE.
I hypothesized that B cells would behave like T cells in their recruitment to the inflamed
CNS in that they would have to be activated, to gain entry and be specific for CNS antigen
to be retained (Fig 1.1). To determine whether antigen specific B cells accumulate in the
CNS, I transferred fluorescent MOG-specific B and T cells into non-fluorescent recipient
mice to track antigen-specific cells throughout disease. Histology and flow cytometry were
completed to elucidate the phenotype of these B cells, comparing them to various B cell
populations (naïve or GC B cells). Further analysis on the role of B cells in CNS
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pathogenies will be explored with initial analysis focused on their role in antigen
presentation and interactions with T cells (e.g. CD80, MHC class II, ICOSL, and SLAM
family receptors), although if other proinflammatory mechanisms are uncovered (e.g.
cytokine production) these will also be pursued.

24

Figure 1.1 | Proposed Model of B cell recruitment to the inflamed CNS.
During CNS autoimmunity we propose that autoreactive myelin specific CD4+ T cells (red)
and myelin-specific B cells (green) are primed and activated in the periphery. This allows
them to cross the BBB and make it into the inflamed CNS (2). Once there, they must find
their respective antigen and be reactivated (3) in order to be retained which leads to the
downstream effects of demyelination (4). This figure was adapted from Goverman, 2009
(87) and was created with BioRender.com.
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1.5.2 Rationale for Chapter 4: Systemic administration of anti-CD20
indirectly reduces B cells in the inflamed meninges in a
chronic model of central nervous system autoimmunity
While B cell depleting therapies have been effective in the treatment of MS (3, 5, 6, 168),
little is known about how these therapies result in their beneficial effects, and whether
meningeal B cell clusters are susceptible to depletion. Previously published data from our
lab has shown that meningeal B cell cluster size and number correlates to disease severity
(217). Since B cell deleting therapies have been highly effective in treating progressive
multiple sclerosis, a course that has been correlated to the presence of B cell follicles in the
meninges (42, 64, 65), I hypothesized this drug has a role in targeting CNS B cells. To
understand the contribution of meningeal B cells to CNS autoimmunity, I characterized
their susceptibility to B cell depletion during the chronic phase of disease using the 2D2
IgHMOG sEAE model. B cell depletion in the CNS was compared to B cell depletion in the
peripheral blood and secondary lymphoid tissue using flow cytometry and histology. The
degree of CNS pathology was measured by histology, counting the number of infiltrating
cells and the extent of demyelination.
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2 Materials and Methods
2.1 Mice
Wild-type C57BL/6, 2D2 TCR transgenic (213), and OTII TCR-transgenic (OTII) mice
(4194;Tg(TcraTcrb)425Cbn/J) were purchased from the Jackson Laboratory. IgHMOG
MOG-specific BCR knockin mice (214) were received as a gift from Dr. H. Wekerle. B18 mice (240) with a homozygous deletion of the Jκ locus (B1-8 Jκ−/−) (241) were a gift
from Dr. A. Haberman. Mice expressing fluorescent proteins within all nucleated cells,
either dsRed (6051; Tg(CAG-DsRed∗MST)1Nagy/J) under control of the β-Actin
promoter or eGFP via the ubiquitin promoter [4353; Tg(UBC-GFP)30Scha/J] were
obtained from the Jackson Laboratory. All mice were housed under specific pathogen-free
conditions at the West Valley Barrier Facility at Western University Canada. Animal
protocols (number 2019-123) were approved by the Western University Animal Use
Subcommittee (Appendix B).

2.2 Adoptive transfer
Naive Ag-specific T and B cells were isolated from either RFP+ 2D2 and GFP+ IgHMOG or
RFP+ IgHMOG mice, respectively, as previously described (242). Hapten-specific GFP+ B
cells were similarly isolated from GFP+ B1-8 Jκ–deficient mice representing foreign
specific B cells, and nonspecific T and B cells were isolated from RFP+ and GFP+ C57BL/6
mice respectively, when noted. Briefly, lymph nodes and spleens of donor mice (as
indicated) were dissociated, and T or B cells were isolated using EasySep Negative
selection Mouse T and B cell Enrichment Kits (StemCell Technologies). Cells were
transferred intravenously (i.v.) into wild-type C57BL/6 recipients, or in some experiments,
OTII (foreign T cell specific mice) or B1-8 Jκ−/− mice (foreign B cell specific mice). Unless
otherwise stated, 5 × 105 T cells and 5 × 106 B cells per mouse were transferred 2 d prior
to immunization.

28

2.3 Induction of EAE
To induce a T and B cell autoimmune response targeting MOG-self–antigen I used a novel
fusion protein Ag based on the extracellular domain of mouse MOG [mMOGtag (202)].
mMOGtag protein was isolated and purified as previously described (211). Mice 6–8 wk
old were immunized subcutaneously at two sites on each flank with a total of 0.5 mg of
mMOGtag (and 0.5 mg nitrophenol [NP]-mMOGtag, when indicated) in CFA (SigmaAldrich). On days 0 and 2 following immunization, mice were administered 250ng of
pertussis toxin (PTX) intraperitoneally (i.p.) (List Biological Laboratories). Clinical
disease was monitored daily and scored as follows: 0, no clinical signs; 1, tail paralysis; 2,
tail paralysis and hind limb weakness; 3, hind limb paralysis; and 4, complete hind limb
paralysis and front limb weakness. Half points were given for intermediate scores.
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Figure 2.1 | Model of adoptive transfers for tracking myelin specific B and T cells during
EAE induction.
To track myelin specific B and T cells during EAE, IgHMOG mice bearing B cells with a
MOG-specific BCR knockin (214) were bred onto a green fluorescent background, while
2D2 transgenic mice bearing T cells with a MOG35-55 TCR (213) were bred onto a red
fluorescent background. These cells were then transferred into wild type C57BL/6 mice
in order to track where myelin specific cells home. Mice were then immunized with
mMOGtag antigen 2d post transfer to induce EAE. When comparing autoimmune myelin
specific B cells to foreign specific B cells, B1-8 J-/- mice were used where >95% of B
cells are specific for the irrelevant NP hapten Ag (241). Finally, to exclude the
endogenous autoimmune response, cells were transferred into B1-8 J-/- mice to exclude
the B cells endogenous response or OTII transgenic mice to exclude the T cell
endogenous response. This figure was created with BioRender.com.
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2.4 Spontaneous 2D2 IgHMOG EAE model
IgHMOG+/+ mice were crossed with 2D2+/- mice. Approximately 80% of IgHMOG+/- 2D2+/double mutant offspring spontaneously result in EAE (sEAE) at 31 – 42 days of age. Only
mice that developed signs of disease and met the conditions of chronic disease were
included in experiments. As both sexes develop chronic disease, both male and female
mice were used in experiments. Clinical disease was monitored daily with a modified 0-20
clinical scoring system to better evaluate tail paralysis, weakness and paralysis for each
individual limb, and righting reflex, with more sensitivity then the typical 5-point scale.
Scores were determined as follows, tails were scored as: 0, asymptomatic; 2, partial tail
paralysis; 4, complete tail paralysis. Each hind limb was scored as: 0, asymptomatic; 1,
hind limb weakness with a wobbly gait; 2, weight bearing but knuckling; 3, not weight
bearing; 4, complete hind limb paralysis. Each forelimb was scored as: 0, asymptomatic;
1, weak grasp yet weight bearing; 2, not weight bearing; 3, complete forelimb paralysis.
Finally, the righting reflex was assessed as: 0, asymptomatic; 1, delayed righting reflex; 2,
no righting reflex.

2.5 Abs for flow cytometry and histology
The following Abs were purchased from BD Biosciences: anti-CD4-V450 (RM4-5), antiCD45R-V450 (RA3-6B2), anti-CD138-BV421 (281–2), anti-CD19-BV711 (1D3), antiCD95-PE-Cy7 (Jo2), anti-Bcl6-A647 (K112-91), anti-CD4-A647 (RM4-5), anti-CD62LA700 (MEL-14), anti-IgG1-APC (A85-1), anti-IgG2a-biotin (R19-15), anti-CD45R-A647
(RA3-6B2), and anti-CD49d-PE-CF594 (R1-2). The following Abs were purchased from
BioLegend: anti-IgKappa-Biotin (RMK-12), anti-IgLambda-Biotin (RML-42), antiCD80-PECy7 (16-10A1), anti-His Tag-purified (J099B12), anti-CD4-A647 (RM4-5),
anti-CD3-A488 (17A2), anti-CD45R-APC-Cy7 (RA3-6B2), anti-Ly6G-A647 (1A8), antirabbit-DyLight555 (Poly4064), anti-CD19-A488 (6D5), anti-GFAP-A488 (2E1.E9), antiIL-17A-PE-Cy7 (TC11-18H10.1), anti-IL-10-A647 (JES5-16E3), and anti-IFN-A700
(XMG1.2). The following Abs were purchased from eBioscience: anti-IgD-eF450 (11–26),
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anti-CD3-FITC (145-SC11), anti-CD38-PE (90), anti-CD4-PE-Cy5 (RM4-5), anti-IgMPE-Cy5 (II/41), anti-CD279-Biotin (RMP1-30), and Streptavidin-APC, StreptavidineF570. FluoroMyelin Red for myelin staining was purchased from Invitrogen. The
following antibodies were purchased from Abcam: Anti-Myelin Basic Protein (MBP)rabbit polyclonal antibody and anti-Ki67 (SP6) unconjugated. The following antibodies
were purchased from Life Technologies: anti-ICOSL-PE (HK5.3), and anti-Ly108-APC
(13G3-19D). mMOGtag was conjugated to Alexa Fluor 647 (mMOGtag-A647) using the
NHS Ester and C2 Maleimide fluorophore labeling kits (Life Technologies) according to
the manufacturer instructions.

2.6 Anti-mCD20 B cell depletion
Anti-mouse-CD20 (5D2), the murine surrogate of rituximab was received as a generous
gift from Genentech, South San Francisco, USA. 150g of the drug was administered i.v.
(unless otherwise stated) during the chronic phase of disease, ~2 weeks post disease onset.
Anti-IgG2a (MG2a-53) acquired from BioLegend was used as an isotype control and
injected at the same concentration i.v. Mice were monitored for EAE disease severity for
either 2- or 7-days following treatment before collecting the blood, lymph node, spleen and
spinal cord for flow cytometry or histology.

2.7 Flow cytometry
The blood, lymph nodes (inguinal, axillary, and cervical), spleen, liver, intestines, and the
spinal cord were harvested from mice for flow cytometry analysis as previously described
(202, 243). Briefly, blood was isolated through a cardiac puncture with needles pre-washed
with 0.5M EDTA. All other tissues were harvested after perfusion with ice-cold PBS.
Individual spinal cords, livers, and intestines were additionally dissociated through a wire
mesh after which leukocytes were isolated using a Percoll (GE Healthcare Life Sciences)
gradient. Leukocytes were collected at the 37/90% Percoll interface. The spleen, blood,
and liver were then lysed for 2 min at 37°C to remove RBCs. Dead cells were identified
by staining with a Fixable Viability Dye eFluor506 (eBioscience) according to
manufacturer’s protocol. All cells were then blocked with an anti-Fc receptor, CD16/32
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2.4G2 (BD biosciences), in PBS containing 2% FBS for 30 min on ice. Cells were then
stained on ice for 30 mins with the listed combination of staining Abs, followed by a
secondary stain with streptavidin for 15 mins on ice where necessary. Spleen cells were
fixed in 2% PFA in PBS prior to running cells to prevent cell clumping. Flow cytometry
was performed on a BD Immunocytometry Systems LSRII cytometer. Analysis was then
completed using FlowJo software (TreeStar).
For cytokine staining, 2 x 106 lymph node cells and 4 x 105 spinal cord cells were stimulated
with cell activation cocktail with brefeldin A (Biolegend) for 2 hrs at 37°C then stained as
listed above. Intracellular staining of IL-10, IFN and IL-17 was completed as previously
described (244). Briefly, cells were fixed and permeabilized with Cytofix / Cytoperm
solution (BD Bioscience) after cell surface staining. Fixed cells were then intracellularly
stained for IL-10, IFN and IL-17 at 4°C overnight. The next day fixed cells were washed,
and flow cytometry was performed as stated above.

2.8 10x Genomics single cell library preparation and Illumina
NextSeq Sequencing
All samples were sequenced at the London Regional Genomics Centre (Robarts Research
Institute, London, Ontario, Canada; http://www.lrgc.ca) using the Illumina NextSeq 500
(Illumina Inc., San Diego, CA). A fully dissociated cell suspension was quantified using
the CellDrop Automated Cell Counter (DeNovix, Wilmington, DE, USA) to measure total
cell counts and cell viability using Acridine Orange / Propidium Iodide (AO/PI) dyes. Two
thousand lymph node and six thousand spinal cord cells were selected for GEM generation
and library construction, as per the user guide (Chromium Next GEM Single Cell 3’
Reagent Kits v3.1 Rev D). Library quantity was determined using the Qubit 2.0
Fluorimeter (Thermo Fisher Scientific, Waltham, MA) and size determined using the
Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA) and the DNA High
Sensitivity kit (Caliper Life Sciences, Mountain View, CA). The library was sequenced on
an Illumina NextSeq 500 as a paired end run, 28 x 91 bp, using a High Output v2 kit (150
cycles).
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Fastq data files were analyzed using Partek Flow (St. Louis, MO). After importation, tags
were trimmed, data was aligned to the Mus musculus mm10 using STAR 2.5.3a and
annotated using Ensembl v98. Unique Molecular Identifiers (UMIs) were de-multiplexed
and quantified to create single cell counts. Guided by violin plots, the cells were filtered
based on total reads > 512, expressed genes >11 and mitochondrial reads percent < 5.50%.
The raw counts data was normalised and clustered using Adobo, and cell types within each
cluster were identified using the Adobo marker-based cell type prediction method (245). B
cells identified in both the spinal cord (129 B cells) and lymph node (661 B cells) samples
were then isolated from the rest of the clusters and fed to Seurat for integration and
differential expression analysis (246).

2.9 Immunofluorescent histology
Spinal cord and lymph node tissue were prepared for histology as previously described
(217). Briefly, at the end of the experiment or earlier, if mice reached a predetermined
endpoint lymph node sections and spinal cord tissue spanning the cervical to lumbar
regions were isolated and fixed in PLP. Spinal cords were then cut into five to nine evenly
spaced sections and frozen in OCT (TissueTek) media. Tissue was then cut in serial
cryostat sections at 7m. Prior to staining, all slide-mounted tissue sections were blocked
with PBS containing 1% BSA, 0.1% Tween-20, and 10% rat serum. After staining, sections
were mounted with ProLong Gold Antifade Reagent (Invitrogen). When staining for MBP,
tissue sections were additionally pre-treated to remove lipids in a series of ethanol gradients
(0%, 50%, 70%, 90%, 95%, 100%, 95%, 90%, 70%, 50% and 0% ethanol in deionized
water for one minute at each concentration) prior to the blocking step. Tiled images of
whole spinal cord sections were collected using a DM5500B fluorescence microscope
(Leica) at 20x.

2.10 Imaging and Statistical analysis
Microscopy images were analyzed using Fiji software. The number of infiltrating B and T
cells were determined by cell counting the number of cells per spinal cord area. The total
area of the spinal cord was determined by either FluoroMyelin staining or glial fibrillary
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acidic protein (GFAP) staining, while regions of demyelination were determined by the
absence of MBP. The percent of demyelination was calculated by dividing the area of
demyelination to the total area of the spinal cord. To determine the size of the cluster area,
I looked at regions of the meninges (determined by the lack of GFAP staining) that
contained B and T cell infiltration.
PRISM software (GraphPad, La Jolla, California) was used for all statistical analysis. A
Student t test was used for single comparisons, and ANOVA followed by a Student t test
with Bonferroni correction was used for multiple comparisons.
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Chapter 3
3

Activated B cells participating in the anti-myelin
response are excluded from the inflamed central
nervous system in various models of autoimmunity that
allows for B cell recognition of autoantigen

Texts and figures within this section were adapted with permission (Appendix A) from the
previously published manuscript:
Tesfagiorgis, Y., S. L. Zhu, R. Jain, and S. M. Kerfoot. 2017. Activated B Cells
Participating in the Anti-Myelin Response Are Excluded from the Inflamed Central
Nervous System in a Model of Autoimmunity that Allows for B Cell Recognition of
Autoantigen. J. Immunol. 199: 449–457.
Copyright©. The American Association of Immunologists, Inc. (AAI).
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3.1 Introduction
Multiple sclerosis (MS) is a chronic disease characterized by inflammation of the central
nervous system (CNS) and demyelination of axons, thought to be driven by an autoimmune
response targeting myelin antigens (247, 248). The importance of B cells to ongoing
disease was demonstrated by clinical studies using anti-CD20 Abs to deplete B cells in MS
patients (225). This finding is complicated by subsequent studies using a different approach
to deplete B cells through the blockade of BAFF and APRIL, key cytokines that drive B
cell proliferation, maturation, and survival. In contrast to CD20-targeting therapies, there
was no evidence of benefit and, instead, disease may have been accelerated (172).
Therefore, although B cells as a whole are major players in disease, there is an urgent need
to identify the pathogenic and protective subsets and the mechanisms by which they
influence disease.
The B cell lineage is best known for production of Abs, via plasmablasts and plasma cells,
which target immune effector mechanisms to specific antigens. However, plasma cells are
not depleted by anti-CD20, nor are Ab levels effected in the therapeutic time frame (225,
249). Therefore, although Abs may contribute to MS, they are not the primary mechanism
by which B cells drive disease. B cells may also contribute to MS by influencing
inflammation and the autoimmune T cell response through production of cytokines or by
acting as APC (250, 251). Particular attention has recently been paid to B cells that infiltrate
the CNS in MS (252). Indeed, several studies of human tissue (42, 43, 63–68) and in animal
models (218, 210, 217, 202, 199, 253, 254) describe B cell accumulation specifically within
the meninges, often forming clusters immediately adjacent to demyelinating lesions.
Consensus is forming around the hypothesis that these are sites where activated
autoimmune B cells promote pathology from within the CNS in MS (251, 252, 255).
Some studies of human MS brain tissue report that meningeal B cells assemble into highly
organized follicles separated from T cell zones (64, 66, 67, 218). Like the structures in
lymph nodes that they resemble, these so-called tertiary lymphatic tissues may be capable
of sustaining GC responses in which antigen specific B cell clones proliferate and
differentiate into memory and effector subsets (256). Similarly, antibody producing plasma
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cells have been described in MS brain tissue (43, 64, 65, 69). In more recent studies,
evidence of class switch and accumulation of somatic mutations was found in BCR genes
isolated from MS brain tissue (143, 251), both of which are strong indicators that B cells
in the CNS derive from a GC response. The apparent accumulation of antigen experienced
B cell clones indicates that they may be responding to an autoantigen present in the tissue.
Nevertheless, much less is known about B cell pathological mechanisms and B cell
invasion of the inflamed CNS in autoimmune disease compared with what is known about
T cells. It is well established that, as with other tissues, antigen activated T cells are able
to gain access to the CNS and that those T cells that encounter their specific antigen within
the tissue are retained and reactivated to exert their effector function (87). The evidence
presented above suggests that the same may also be true of B cells, but this has not yet
been demonstrated.
I set out to define the B cell relationship with the inflamed CNS in anti-myelin
autoimmunity using both an inducible and spontaneous mouse model of experimental
autoimmune encephalomyelitis (EAE). The inducible model results from immunization of
C57BL/6 mice with a fusion-protein based on the extracellular domain of mouse myelin
oligodendrocyte glycoprotein (mMOGtag) (211). Our lab has previously demonstrated that,
unlike most models used currently, the inducible model incorporates both T and B cell
recognition of the autoantigen (202). By tracking transferred T and B cells with known
specificity for MOG, I was surprised to find that, although activated autoimmune T cells
are enriched in the diseased CNS as expected, the opposite was true of myelin-specific B
cells. This finding was further corroborated by the utilization of a different B-cell
dependent spontaneous model of EAE that develops in mice expressing both 2D2 TCRs
specific for MOG35-55 (213) crossed with IgHMOG BCRs specific for MOG1-125 (214). This
model resulted in mice with mMOGtag specificity excluded from the inflamed CNS. This
finding is a significant challenge to our assumptions about how B cells contribute to
autoimmune disease pathology from within the CNS.
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3.2 Results
3.2.1 Activated, autoimmune T cells are enriched in the inflamed
spinal cords of mMOGtag-induced EAE mice
Our lab recently demonstrated that immunization of C57BL/6 mice with a novel protein
Ag based on the extracellular domain of mMOGtag results in chronic CNS autoimmunity
driven by both anti-myelin T and B cells (202). To identify and track the location and
differentiation of pathogenic autoimmune cells over the course of the disease, I transferred
fluorescent anti-MOG T and B cells to nonfluorescent recipient mice prior to disease
induction. Red fluorescent T cells were isolated from 2D2 TCR transgenic mice that also
ubiquitously express RFP, and green fluorescent B cells were isolated from IgHMOG BCR
H chain knockin mice that also ubiquitously express GFP. These cells were transferred to
wild-type C57BL/6 mice 2 d prior to immunization with mMOGtag in CFA and i.p.
administration of PTX to induce disease. Our lab previously showed that immunization
induces a large expansion of the transferred autoimmune T and B cells via a germinal center
response (202).
Consistent with our previous observations (202), immunized mice developed physical
signs of disease ∼5 d post immunization (Fig. 3.1A). Diseased mice were sacrificed 11 d
post immunization in the acute phase of disease, and spinal cords were harvested for
immunofluorescence analysis of pathology and inflammation. Extensive pathology was
evident throughout the spinal cord featuring large regions of white matter demyelination
associated with CD4+ T cell (Fig. 3.1B) and CD8+ T cell (data not shown) infiltration.
CD45R+ B cells were largely confined to the meninges, often directly adjacent to
underlying demyelinating lesions (Fig. 3.1B).
It is well established that activated but not naive T cells are able to gain access to the
noninflamed CNS, and that encountering a specific Ag is required for retention of a T cell
in the tissue (77). Although the literature typically generalizes this to include the inflamed
CNS in EAE, the evidence for this is limited. Using intravital microscopy of the pial
microvasculature in a rat model of EAE, Bartholomäus et al. (84) observed endothelial
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transmigration of activated T cells regardless of specificity, but noted that only myelinspecific cells were able to migrate away from the immediate vicinity of the vessel.
However, our analysis of T cell infiltration of the spinal cords of mice described above
revealed that both RFP+ 2D2 and RFP− endogenous CD4+ T cells were evident throughout
the white matter and meninges (Fig. 3.1C). The proportion of infiltrating CD4+ T cells that
were RFP+ was variable between individual mice (Fig. 3.1D), yet in most cases exceeded
the proportion of RFP+ cells observed in the inguinal lymph nodes in which the anti-MOG
response itself was initiated (never exceeding 2–44% as determined by flow cytometry;
data not shown). The relative enrichment for MOG-specific RFP+ T cells in the inflamed
CNS was confirmed in a separate experiment that used flow cytometry to quantify the
accumulation of RFP+ T cells in the spinal cord, circulation, and lymphoid tissues of EAE
mice. Indeed, RFP+ cells made up a greater percentage of the total CD4+ T cell population
in the spinal cord compared with circulating blood, spleen, lymph nodes, or draining
inguinal lymph nodes (Fig. 3.1E).
In the above experiments it is likely that recipient-derived nonfluorescent MOG-specific T
cells also responded to mMOGtag immunization. Therefore, at least some of the infiltrating
RFP− T cells observed in the spinal cord may have also been MOG specific, potentially
resulting in an underestimation of enrichment for MOG specificity. To largely limit the
anti-MOG T cell response to transferred RFP+ 2D2 T cells, OTII mice in which the great
majority of T cells express an irrelevant TCR against the foreign Ag OVA were used as
recipients. Following transfer of fluorescent MOG-specific T and B cells as described
above, OTII recipients developed disease in response to immunization with mMOGtag (Fig.
3.1F). Again, RFP+ cells made up a large proportion, but not all, of the infiltrating CD4+ T
cells (Fig. 3.1D). Therefore, although MOG-specific T cells are highly enriched in the
inflamed spinal cord in EAE, Ag specificity is not likely to be an absolute requirement.
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Figure 3.1 | CNS infiltrating T cells are enriched for autoimmune T cells.
GFP+ IgHMOG B cells and RFP+ 2D2 T cells were transferred into wild type nonfluorescent
C57BL/6 recipients 2 d prior to induction of EAE via immunization with mMOGtag in CFA
and i.p. administration of PTX. Mice were monitored daily for signs of disease (A). Note
that disease scores are shown only for mice that developed disease. (B) Representative
immunofluorescence image of a spinal cord section collected 11 d post immunization from
an EAE mouse demonstrating T and B cell infiltration and demyelination. Regions
depicting myelin loss are starred. (C) Representative serial sections demonstrating a region
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of extensive myelin loss in the white matter (top; myelin loss is starred) and extensive
infiltration of CD4+ cells, many of which were also RFP+ indicating they derived from our
transferred 2D2 RFP+ T cells (top and bottom). (D) CD4+ cells in spinal cord sections of
C57BL/6 or OTII-recipient EAE mice (F) were quantified and the percent of RFP+ cells is
shown. Each symbol represents an individual mouse from three pooled independent
experiments (C57BL/6) or a single OTII experiment. (E) Fluorescent MOG-specific T and
B cells were transferred to wild-type C57BL/6 recipients prior to EAE induction as
described above. Then 20 d post immunization, circulating blood, pooled lymph nodes
(LN), draining inguinal lymph nodes (dLN), and spinal cord (SC) were analyzed by flow
cytometry. The percent of CD4+ cells that are also RFP+ is shown for each tissue. Each
symbol represents an individual mouse. (F) Disease scores for OTII recipient EAE mice
used for analysis of RFP+ T cell infiltration of the spinal cord shown in (D). Two mice
reached disease severity endpoint and were sacrificed early (dotted arrow) and remaining
mice were sacrificed at the solid arrow. Scale bars, 100 μm. Data is shown as mean +/SEM.
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Flow cytometry analysis revealed that spinal cord T cells express higher levels of the
activation marker CD44 and lower levels of CD62L compared with lymph node T cells
(Fig. 3.2A, 3.2B). By histology, a slight majority of both RFP+ 2D2 T cells and endogenous
RFP− T cells co-stained with CD44, regardless of whether C57BL/6 or OTII recipient mice
were used (Fig. 3.2C). Similarly, both RFP+ and RFP− T cells stained for intracellular Ki67
in approximately equal numbers (Fig. 3.2D), indicating that many were in cell cycle.
However, I observed no evidence that T cells in either the meninges or infiltrating deeper
into the CNS parenchyma expressed PD-1 (data not shown), excluding the possibility that
they were either T follicular helper cells or exhausted T cells. Therefore, consistent with
established rules for T cell surveillance of the healthy CNS (77), activated anti-myelin T
cells are highly enriched in the inflamed CNS in autoimmunity.
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Figure 3.2 | Infiltrating T cells have an activated phenotype regardless of anti-myelin
specificity.
GFP+ IgHMOG B cells and RFP+ 2D2 T cells were transferred into C57BL/6 recipients, 2 d
prior to induction of EAE. Lymph nodes and spinal cords were harvested from diseased
mice 20 d post mMOGtag immunization and CD4+ T cells were analyzed by flow
cytometry. (A) Representative histograms of the mean fluorescence intensity of CD44 (top)
and CD62L (bottom) staining of CD4+ RFP+ cells isolated from the inguinal lymph node
or the CNS of the same mouse. (B) Mean fluorescent intensity (MFI) of CD44 (top) and
CD62L (bottom) staining of endogenous RFP− and transfer-derived RFP+ CD4+ T cells
from lymph nodes or spinal cords. Each symbol represents an individual mouse. *p < 0.05,
**p < 0.01. (C) In two separate similar experiments in which MOG-specific T and B cells
were transferred into either C57BL/6- (left) or OTII- (right) recipient mice, spinal cords
were harvested and prepared for immunofluorescence staining to characterize infiltrating
immune cells (disease score shown in Fig. 1F). The percentage of RFP− and RFP+ CD4+ T
cells co-staining with CD44 was quantified. Each symbol represents an individual mouse.
(D) Representative image from the C57BL/6-recpient experiment as described in Fig. 1A
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showing Ki67 staining of both RFP+ (squares) and RFP− (circles) CD4+ T cells in the spinal
cord of an EAE mouse. Scale bars, 100 μm.
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3.2.2 Autoimmune B cells are excluded from the inflamed spinal
cords of mMOGtag-induced EAE mice
The analysis above confirms that activated, myelin-specific T cells are highly enriched in
the inflamed CNS in anti-myelin autoimmunity. To determine if the same is true for
infiltrating B cells, spinal cord sections from the experiment described above (Fig. 3.1A)
were separately analyzed for B cell infiltration and accumulation of GFP+ IgHMOG B cells.
As noted above, CD45R+ B cells were largely confined to the meninges (Fig. 3.1A) and
were only very rarely observed in the parenchyma (data not shown; also see below).
Surprisingly, no GFP+ B cells were found in any of the sections I investigated (example
shown in Fig. 3.3A). By flow cytometry, GFP+ B cells were evident in the draining inguinal
lymph nodes of the same mice (Fig. 3.3B), confirming that the transfer and activation of
IgHMOG B cells was successful. Further, both RFP+ T cells and GFP+ B cells were clearly
evident by histology in lymph nodes harvested from separate mice at a similar timepoint
(Fig. 3.3C), confirming both that immunization with mMOGtag induced a germinal center
response incorporating the progeny of the transferred MOG-specific T and B cells, and that
GFP+ B cells can be detected by histology if they are present in the tissue. The exclusion
of GFP+ B cells from the CNS was further confirmed in a separate experiment using flow
cytometry to analyze diseased spinal cord, circulating blood, and lymphatic tissue
harvested from mMOGtag-induced EAE mice. Although GFP+ B cells were evident in
peripheral tissues, they were completely absent from the CNS (Fig. 3.3D).
Finally, a similar experiment was performed to track GFP+ MOG-specific B cells in
preclinical mice to determine if autoimmune cells are present in the CNS at an earlier
timepoint. Again, although RFP+ MOG-specific T cells were readily apparent in the spinal
cords of mMOGtag-immunized mice (data not shown), GFP+ cells were absent from the
spinal cords (Fig. 3.3E), but detectable in the draining inguinal lymph nodes, other
lymphatic tissues (other peripheral lymph nodes and spleen) and liver. Except for a single
mouse, very few were observed in the intestines.
As for T cells, nonfluorescent, C57BL/6 recipient-derived B cells would also be able to
respond to immunization with mMOGtag. Therefore, it is possible that GFP− B cells
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infiltrating the spinal cord were myelin specific and somehow outcompeted the transferred
GFP+ IgHMOG cells for access to the tissue. To exclude this possibility, fluorescent IgHMOG
B cells were transferred to B1-8 Jκ−/− recipient mice in which >95% of B cells are specific
for the irrelevant NP hapten Ag (241), effectively preventing an endogenous anti-MOG
response. Disease was induced via immunization with mMOGtag, as described above (Fig.
3.3F). Again, meningeal B cell clusters were clearly evident in the spinal cords of diseased
mice (Fig. 3.3G, left). CD45R+ cells were only very rarely observed in the white matter
parenchyma (Fig. 3.3G, right). No GFP+ MOG-specific B cells were observed in any
section imaged. Therefore, anti-MOG B cells are excluded from the inflamed tissue in a
model of CNS autoimmunity that incorporates B cell activation and recognition of myelin
Ag (202).
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Figure 3.3 | Autoimmune B cells are excluded from the inflamed spinal cords of mMOGtaginduced EAE.
GFP+ IgHMOG B cells and RFP+ 2D2 T cells were transferred into wild-type nonfluorescent
C57BL/6 recipients 2 d prior to induction of EAE (disease score shown in Fig. 1A) (A)
Representative immunofluorescence image of a spinal cord section showing a meningeal
B cell cluster devoid of transfer-derived GFP+ B cells. (B) Flow cytometry analysis of the
inguinal lymph nodes of the same mouse demonstrating the presence of GFP+ B cells. (C)
In a separate experiment, RFP+ and GFP+ MOG-specific T and B cells were transferred
into C57BL/6 recipient mice and 2 d later mMOGtag was administered via footpad
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injection. Immunofluorescence analysis of a draining inguinal lymph node harvested 10 d
post immunization reveals the presence of MOG-specific RFP+ T cells and GFP+ B cells.
(D) As described in Fig. 1E, fluorescent MOG-specific T and B cells were transferred to
wild-type C57BL/6 recipients prior to EAE induction. 20 d post immunization, circulating
blood (Blood), pooled lymph nodes (LN), draining inguinal lymph nodes (dLN), and spinal
cord (SC) were analyzed by flow cytometry. The percent of CD45R+ CD19+ cells that are
also GFP+ is shown for each tissue. (E) In a separate experiment, MOG-specific RFP+ T
cells and GFP+ B cells were transferred into nonfluorescent C57BL/6 recipient mice 2 d
prior to induction of EAE. Then 8 d post immunization, cells isolated from the dLN, LN,
spleen (SP), intestine (In), liver (Li), and SC were analyzed by flow cytometry. Each
symbol represents an individual mouse. Comparisons between multiple groups were done
using a one-way ANOVA with Bonferroni correction, * p < 0.05, ** p < 0.01, *** p <
0.001. (F) In two separate but repeat experiments, fluorescent MOG-specific T and B cells
were transferred to B1-8 Jκ−/− recipient mice bearing a mutant BCR specific for an
irrelevant Ag. One experiment with n = 4 ended 18 d post immunization (dotted arrow),
whereas the other went out 34 d (n = 2). Errors bars represent SEM. (G)
Immunofluorescence was performed on spinal cords harvested 34 d post mMOGtag
immunization. One representative image is shown of a typical meningeal B cell cluster
devoid of GFP+ cells. One infiltrating parenchymal B cell (closed triangle) was evident in
the white matter of a diseased mouse (see inset box shown at higher magnification, right).
Scale bars, 100 μm.
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3.2.3 Activated B cells are excluded from the inflamed spinal cords of
mMOGtag-induced EAE mice
In the above experiments transferred GFP+ B cells may have been excluded due to their
specificity for a CNS Ag or alternatively due to their activation status. To differentiate
between these possibilities, I transferred both RFP+ IgHMOG MOG-specific B cells and
GFP+ NP-specific B1-8 Jκ−/− B cells into nonfluorescent wild-type C57BL/6 mice.
Recipients were immunized with both mMOGtag and NP-haptenated mMOGtag in CFA.
Disease developed normally in these mice (Fig. 3.4A) and draining inguinal lymph nodes
and spinal cords were harvested for analysis 21 d post immunization. Flow cytometry
analysis of the lymph nodes confirmed that both transferred MOG-specific RFP+ and NPspecific GFP+ B cells were activated and proliferated in response to immunization with the
combined antigen (Fig. 3.4B, left). Despite this, neither RFP+ nor GFP+ B cells were
present in the spinal cords of diseased mice (Fig. 3.4B, right; 3.4C). This suggests that
activated B cells, regardless of specificity, are excluded from the inflamed CNS.
Phenotypic analysis of CNS-infiltrating B cells supports the contention that they are not
activated in a conventional way, as occurs in response to specific antigen in lymphatic
tissue. By flow cytometry, spinal cord B cells were exclusively CD38hi CD95lo, a
phenotype shared by naive and memory B cells (Fig. 3.4D). However, compared with
lymph node B cells of the same CD38hi CD95lo phenotype, spinal cord B cells expressed
elevated levels of surface CD80 (Fig. 3.4E), indicating that they are activated to some
degree. Importantly, this phenotype is identical to that of spinal cord B cells, which our lab
recently described in a different B cell–dependent EAE model that develops spontaneously
in mice expressing both the 2D2 TCR and IgHMOG BCR (217), therefore it is not an artifact
unique to the mMOGtag-induced model.
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Figure 3.4 | Activated B cells are excluded from the inflamed CNS in MOGtag-induced
EAE.
RFP+ IgHMOG and GFP+ B1-8 Jκ−/− B cells were transferred into C57BL/6 mice 2 d prior
to immunization with both mMOGtag and NP-MOGtag in CFA, accompanied by PTX i.p.
Mice were monitored daily for signs of disease (A). Then 21 d post immunization, lymph
nodes and spinal cords were harvested from sick mice and analyzed by flow cytometry for
the presence of RFP+ and GFP+ B cells (B and C). One representative set of plots (n = 4)
for a lymph node (left) and spinal cord (right) from the same mouse is shown in (B). Each
data point represents an individual mouse in (C). *p < 0.05, **p < 0.01. (D) In a separate
experiment, GFP+ IgHMOG B cells and RFP+ 2D2 T cells were transferred to C57BL/6
recipients 2 d prior to EAE induction. Lymph nodes and spinal cords were harvested from
sick mice 20 d post immunization and analyzed by flow cytometry. Representative plots
gated on B cells (left) show the presence of GFP+ B cells in lymph nodes (top) but not the
spinal cord (bottom). The CD38/CD95 expression profile of GFP− B cells was further
analyzed to determine activation status (right). (E) CD80 expression by naive/memory
phenotype B cells (CD38hi CD95lo) from the lymph node and spinal cord (arrow) was
quantified. Each symbol represents an individual mouse. Data is shown as mean +/- SEM.
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In a repeat experiment with no MOG-specific B and T cell transfer (disease scores shown
in Fig 3.5A), surface receptor expression of ICOSL, Ly108, and CD49d on B cells in the
inflamed CNS compared to peripheral lymph node B cells was analyzed. Interestingly, a
bimodal relationship was observed for B cells expressing ICOSL (Fig 3.5B), with some B
cells upregulating the expression of ICOSL relative to LN B cells, while other B cells do
not. This represents the first observation of two distinct B cell population in the inflamed
CNS in mMOGtag induced EAE. B cell expression of Ly108 was significantly upregulated
in the inflamed spinal cord (Figure 3.5C, left), while despite all B cells expressing CD49d
(4-integrin), they had a slight downregulation (Figure 3.5C, right) in comparison to lymph
node B cells.

Figure 3.5 | B cells in the inflamed CNS upregulate the expression of ICOSL and Ly108.
C57Bl/6 recipient mice were immunized with mMOGtag and during the chronic phase of
disease (d16 post disease onset, [A]), lymph nodes and spinal cords were harvested from
mice and analyzed by flow cytometry (n=3). B cell surface expression of ICOSL (B),
Ly108 and CD49d (C) were quantified in the lymph node and spinal cord. Each symbol
represents an individual mouse. Comparisons were done using a paired two-tailed
Student’s T-test, **p < 0.01. Data is shown as mean +/- SEM.
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Follow-up analysis by histology did not find any evidence of class switch in meningeal B
cells, as they were exclusively IgD+ and no IgG1+ cells were observed (Fig. 3.6A).
Parenchymal B cells were too rare to analyze reliably. Further, I did not find any evidence
of plasma cells in spinal cord tissue as indicated by the absence of cells with the
intracellular L chain (data not shown), an indicator of large-scale Ab production, which is
a fundamental property of plasma cells. In contrast to T cells (see above), very few B cells
in the meninges or rare parenchymal cells stained with Ki67 (Fig. 3.6B), indicating that the
large majority were not proliferating.

Figure 3.6 | B cells in the inflamed CNS are not actively proliferating and are IgD+.
(A) Serial sections of spinal cord tissue from the experiment described in Fig 1A were
stained by immunofluorescence showing no Ki67 staining of meningeal B cells. (B) IgD
(bottom left) but no IgG (bottom right) staining, was observed in the spinal cord of diseased
mice. Lymph nodes were stained as a positive control (top). Scale bars, 100 μm.
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To determine if unactivated, naive B cells are able to access the CNS in EAE and to confirm
that B cell exclusion from the CNS was not due to their expression of GFP or due to the
method of cell transfer, B cells were isolated from GFP-expressing but otherwise wild-type
mice and transferred to already immunized mice at the preclinical stage of disease (day 6
post immunization). Two days post transfer, draining inguinal lymph nodes, pooled lymph
nodes, and spinal cords were harvested for analysis by flow cytometry. As expected, GFP+
B cells were recovered from lymph nodes (Fig. 3.7A), consistent with normal homing of
naive cells to lymphatic tissue. Small numbers of GFP+ cells were also recovered from
spinal cords and, although very rare in absolute terms (data not shown), the proportion of
total B cells isolated from spinal cords that were GFP+ was not significantly different from
lymphatic tissue. Similarly, in a separate experiment RFP+ IgHMOG and GFP+ B1-8 Jκ−/− B
cells were isolated from unimmunized mice and transferred into recipients with already
established mMOGtag-induced EAE (Fig. 3.7B). Two days post transfer, draining inguinal
lymph nodes, pooled lymph nodes, and spinal cords were harvested for analysis by flow
cytometry. Both GFP+ and RFP+ B cells were recovered from lymph nodes, (Fig. 3.7C)
and, consistent with the previous experiment, even though in absolute terms the number of
transferred B cells recovered from the spinal cord was very small (Fig. 3.7C, left), they
made up a similar proportion of total B cells recovered from both tissues (Fig. 3.7C, right).
No significant bias between NP- or MOG-specific B cells was observed, suggesting that
the activation state rather than specificity is the primary factor limiting initial access to the
tissue. Together, these experiments suggest that, unlike activated B cells, small numbers of
unactivated cells are recruited to the inflamed spinal cord in EAE. However, because
transferred B cells make up a similar proportion of the total B cell pool, the relative rate of
recruitment is similar in the spinal cord and lymphatic tissue. The complete absence of
MOG-specific B cells observed in previous experiments could be due to the subsequent
removal or loss of cells that encounter Ag once in the CNS, or because all Ag-specific cells
were activated by immunization.
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Figure 3.7 | Naive B cells can access the inflamed CNS.
EAE was induced in C57BL/6 mice and 6 d post immunization wild-type RFP+ T cell and
GFP+ B cells were transferred i.v. into recipient mice (A). Then 2 d later mice were
sacrificed and inguinal lymph nodes that drain the site of immunization (dLN), axial and
brachial lymph nodes (LN), and spinal cords (SC) were analyzed by flow cytometry for
the presence of nonspecific GFP+ B cells. (B) In a separate experiment EAE was induced
in C57BL/6 mice. Once disease was established, RFP+ IgHMOG B cells and GFP+ B1-8 Jκ−/−
B cells were isolated from healthy donor mice and transferred i.v. into the already sick
EAE recipient mice (timepoint of transfer indicated by the arrow). Errors bars represent
SEM. (C) After 2 d mice were sacrificed and LN, dLN, and the SC were analyzed by flow
cytometry for the presence of both the absolute number (left) and percent of (right) RFP+
and GFP+ B cells. Each symbol represents an individual mouse. ** p < 0.01, **** p <
0.0001.
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3.2.4 B cell phenotype in the inflamed spinal cord of sEAE is similar
to mMOGtag induced EAE
Previous work from our lab identified a positive correlation between B cell infiltration in
the spinal cord and disease severity (217), using the sEAE model (Fig 3.8A). To confirm
whether the phenotype of activated, autoimmune B cells being excluded from the inflamed
CNS occurs in this model of EAE, I characterized the antigen specificity of B cells within
the inflamed CNS of chronic sEAE mice. To do this I conjugated mMOGtag to Alexa Fluor
647 (mMOGtag-A647) to identify B cells specific for mMOGtag by flow cytometry.
Consistent with the inducible mMOGtag model, B cells isolated from the inflamed CNS of
chronic sEAE (~2wks post disease onset [Fig 3.8B]) had significantly reduced specificity
for mMOGtag compared to B cells isolated from peripheral LNs (Fig 3.8C). Follow-up
analysis by immunofluorescence microscopy in a separate repeat experiment revealed little
to no evidence of class switch in meningeal B cells with the large majority being IgD+ (Fig
3.8D, left) and only rare IgG1+ B cells observed (Fig 3.8D, right). MHC class II expression
was also observed on all CNS infiltrating B cells (Fig 3.8E).
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Figure 3.8 | B cells in the inflamed CNS of sEAE are not specific for MOG antigen and
are predominately not class switched.
Double mutant offspring from the F1 generation of 2D2 mice crossed with IgHMOG mice
(A) were monitored and scored daily for signs of sEAE (B). Data is shown as mean +/SEM. The peripheral lymph nodes (axial, brachial and inguinal [LN]) and spinal cord (SC)
were harvested from chronic sEAE mice (sick 22 days post onset) and cells were prepared
and analyzed by flow cytometry. (C) CD19+ CD45R+ B cells were analyzed for their
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specificity for mMOGtag using mMOGtag conjugated to Alexa Fluor 647. A representative
flow plot of B cells in the spinal cord is shown on the right. Each symbol represents an
individual mouse. Comparisons were done using a paired two-tailed Student’s T-test,
*p<0.05., ****p<0.0001. In a repeat experiment once, disease was established (sick 20
days post onset), serial sections of spinal cord tissue were stained by immunofluorescence
to characterize infiltrating B cells. (D, left) Nearly all CD45R+ B cells in the CNS costained with IgD while few IgG positive B cells observed (D, right, closed triangle). Lymph
nodes were stained as a positive control (D, bottom). All CD45R+ B cells also co-stained
with MHC class II (E). Demyelination can be observed by loss of myelin (MBP) within
the total spinal cord area delineated by GFAP staining. Representative images from 2 mice
are shown (n = 6).
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In the same experiment from above (Fig. 3.8B), cells were taken from the spinal cords and
peripheral lymph nodes of three male mice for single-cell RNA sequencing (sc-RNA-seq)
analysis using a 10x genomics chromium controller. Information on the severity and days
post onset (duration of disease) of these mice can be found in Table 1. Preliminary analysis
comparing B cells in the spinal cord (Fig 3.9A) to B cells in peripheral lymph nodes (Fig
3.9B) for differentially expressed genes using Seurat revealed 4108 differentially
expressed genes with a p < 0.001, with the top 25 differentially expressed genes expressed
in Fig 3.9B. Overall, this preliminary analysis supports the unique phenotype of B cells
within the inflamed CNS. Future studies comparing B cells in the spinal cord to a more
targeted B cell populations in the lymph node (GC B cells, naïve B cells, memory B cells)
or peritoneal cavity B1 B cells will need to be completed to better characterize the
phenotype of B cells within the inflamed CNS.
Table 1 | Phenotype of mice used in single-cell RNA sequencing experiment.
Average

STDEV

days post onset

17.0

5.29

max score

14.7

1.15

end score

11.3

2.31

n

3
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Figure 3.9 | Single cell-RNA-sequencing analysis reveals a unique B cell population in the
spinal cord of sEAE mice in comparison to lymph node B cells.
Following cell isolation from the lymph node and spinal cord of sEAE mice, two thousand
lymph node cells and six thousand spinal cord cells were selected for generation of single
cell library construction using 10x Genomics and the library was sequenced using an
Illumina NextSeq 500 as a paired end run, 28 x 91 bp, using a High Output v2 kit (150
cycles). Fastq files were analyzed using Partek Flow and data was aligned to the mouse
genome (Mus musculus mm10). Guided by violin plots, the cells were filtered based on
total reads > 512, expressed genes >11 and mitochondrial reads percent < 5.50%. Raw
counts data was normalized and clustered using Adobo, and cell types within each cluster
were identified using Adobo’s marker-based cell type prediction method with the default
parameters for all steps. Labelled cell clusters from the spinal cord (A) and lymph node (B)
are shown. B cell clusters identified using Adobo are labelled with a red circle. (C) Total
B cells from the spinal cord (129 cells) were then compared to B cells in the peripheral
lymph nodes (661 cells) for differentially expressed genes using Seurat.
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3.3 Discussion
Together, our findings suggest that B cells have a very different relationship with the
inflamed CNS in autoimmunity than T cells do, in that antigen specific cells actively
participating in the anti-myelin response are excluded from the tissue rather than enriched.
The absence of activated, autoimmune B cells in the inflamed CNS in two mouse models
of anti-myelin autoimmune disease [in this study and (217)] may be interpreted as being at
odds with findings from studies of human MS. However, close reading of this literature
suggests that this may not be the case (221). Descriptions of B cell infiltration in MS brain
tissues have largely focused on the most highly organized structures resembling lymphoid
tissue that may be able to sustain a germinal center, however, it is clear that most clusters
of B cells in the meninges are much less organized. Not all studies of human MS brain
tissue found evidence of organized tertiary tissues (257), and even those that did report that
most B cells were in less organized clusters not containing germinal centers (42, 43, 64–
69), perhaps more reminiscent of the clusters we have described in our models [in this
study and (202, 217)]. Similarly, although plasma cells have been reported to be in MS
brain tissue (42, 43, 64, 65, 257), this too is not a universal finding (64, 143).
Nevertheless, studies analyzing BCR genes cloned from MS brains report that they are
often class switched and show evidence of accumulating somatic mutations (137, 143,
251), both of which are very strong indications that they come from B cells derived from a
germinal center response. Indeed, a recent important study from Stern et al. (143) traced
the clonal lineage of brain B cells and showed that some were related to B cells found in
deep cervical lymph nodes, building on their previous study demonstrating that B cells in
the meninges are also clonally related to those deeper parenchyma (137). Importantly, they
found no evidence of germinal center responses within the CNS tissues they analyzed, nor
did they observe plasma cells. Therefore, although they provide clear evidence that the B
cells found in MS brains had previously been activated and likely derived from germinal
center responses in cervical lymph nodes, the cells in the tissue were not themselves in an
activated state, at least not in a conventional sense as we understand antigen specific B cell
activation in lymph nodes. Most critically, in a recent follow-up study from the same group,
no evidence was found that BCRs isolated from MS brains recognized CNS or MS-specific
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antigens (146). Therefore, instead of contradicting the human literature, I believe that our
experimental findings in mouse models are entirely consistent with observations of human
MS brain tissue.
This study employs a unique experimental system, adapted from our studies of B cell
responses to foreign model antigens (242), which allows us to identify and track myelinspecific cells throughout the developing autoimmune response and associated disease
pathology. This system depends on the transfer of small numbers of fluorescent T and B
cells with known anti-MOG specificity to nonfluorescent recipients, which are then
activated and expanded to large numbers in lymph nodes via immunization with Ag. The
success of this transfer is demonstrated by the presence of GFP+ cells in draining popliteal
lymph nodes as, in our experience, without immunization transferred naïve B cells are lost
and not detectable in any tissue after a small number of days. Further, as appreciable
numbers of GFP+ B cells were also found in other tissues including noninvolved lymphoid
tissue and the liver, the egress and subsequent recirculation of the progeny of transferred
GFP+ B cells is also not defective. Exclusion from the inflamed CNS may be determined
by recruitment mechanisms limiting that access of newly activated B cells. Alternatively,
myelin-reactive cells may be induced to leave the tissue or die after encountering specific
antigen, although this would likely also be tied to activation status as naive MOG-specific
B cells were detectable in the inflamed CNS for at least 2 d post transfer.
In the work presented in this study I was not able to differentiate between naive and IgM
memory B cells. By definition, memory B cells derive from previously activated cells but
are themselves quiescent (258). Unless they have undergone class switch, memory B cells
are very difficult to differentiate from naive B cells phenotypically. In humans, CD27 is
often used as a surface marker to identify memory B cells and CD27+ B cells have been
reported to be present or even enriched in meningeal clusters in MS (25). Unfortunately,
no equivalent memory marker exists in the mouse model system. Nevertheless, because I
observed virtually no class switch in the meningeal B cells in our model, I suspect that
most were naive, rather than memory. This does contrast with human MS studies that, in
addition to IgM+ B cells, also note IgG and IgA switched cells (111, 143). However,
although this does represent a discrepancy between human MS and our model, it should be
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noted that humans accumulate large numbers of memory B cells over decades of exposure
to numerous pathogens. Like central memory T cells, memory B cells are thought to have
homing properties similar to naive B cells (259) and therefore would accumulate in the
same tissues. Our short-lived mouse models housed under very clean conditions will not
accumulate B cell memory to nearly the same degree and therefore do not recapitulate this
aspect of human disease. This could explain why I only observe apparently naive B cells
in our mouse models, whereas memory cells are reported to be common in human MS
tissue.
The distribution of B cells in the inflamed CNS may represent another discrepancy between
our mouse model and human MS. In our models, B cells in the spinal cord are largely
restricted to the meninges with only very rare cells found deeper in the parenchyma. Some
histological studies of human MS brain tissue do report B cells in the parenchyma and
white matter lesions (137, 223, 260). However, as for descriptions of plasma cells (see
above), parenchymal B cells are not always observed (111). This is further complicated by
descriptions of parenchymal cells as perivascular (25, 137), as these can be considered to
be associated with the pia mater. In the few cases where the distinction is made,
parenchymal B cells not directly associated with a venule are very sparse, as I observe in
our models. Regardless, analysis of BCR genes isolated from the peripheral meninges and
from deeper parenchymal MS brain tissue demonstrated that they were clonally related
(137). While ICOSL staining by flow cytometry revealed two unique populations of B cells
in the spinal cord (which would also incorporate rare parenchymal cells), no evidence by
histology indicated that the rare parenchymal B cells were activated any more than
meningeal cells (by Ki67 staining for example, data not shown).
Regardless of whether they are naive or memory, it is not clear how antigen-nonspecific
meningeal B cells could promote CNS pathology. B cells are capable of presenting antigen
to T cells and the physical association between T and B cells in meningeal clusters in
addition to the elevated expression of CD80 by B cells in the CNS [Fig. 3.4E and (217)]
strongly suggests that this is a role they play within the CNS. The upregulation of ICOSL
in meningeal B cells, as well as Ly108 (Fig 3.5B and C) and presence of MHC class II (Fig
3.8C) also suggest B and T cell interactions (261) and entanglement (262) are occurring.
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However, B cell presentation of antigen is best understood in the context of the germinal
center response where B cells internalize antigen that binds their own specific BCR for
presentation to T cells specific for the same antigen. Little is known about nonspecific Ag
presentation by B cells. Further research is required to determine how B cells acquire their
semi-activated phenotype and if their APC function is indeed enhanced. Future work will
also need to be completed to understand the mechanisms and outcomes of noncognate
interactions with autoimmune T cells in the CNS, as these may differ considerably from
those that occur in the GC response in lymphatic tissue. Although sc-RNA-seq analysis
was presented within this thesis, this analysis was very preliminary and a more targeted
comparison of B cells in the spinal cord to different populations of B cells will be required
in order to better characterize this population of cells.
Finally, the work presented in this study has important implications for our understanding
of the mechanistic contribution(s) of autoimmune B cells to CNS autoimmunity. Both our
lab and others have demonstrated that anti-myelin B cells do indeed contribute to the
incidence and/or severity of disease in models that accommodate B cell recognition of
antigen (202, 203, 215–217). Nevertheless, contrary to our expectations, autoimmune B
cells are excluded from the inflamed site. More studies will be required to determine if this
is a general feature of B cell responses during tissue inflammation or if it is unique to
autoimmunity or the CNS environment. Regardless, I propose a model where B cells
contribute to disease through (at least) two different mechanisms exerted from different
anatomical sites. First, anti-myelin B cells may drive disease from the periphery, perhaps
by influencing T cell activation and in some cases Ab production (221). Second, antigennonspecific cells may contribute to local pathology from within the CNS, although I have
not yet confirmed that this is the case. Potential pathogenic mechanisms include
noncognate antigen presentation to T cells and production of inflammatory mediators.
Investigations of the activation status of meningeal B cells will aid greatly in resolving this
important issue.
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Chapter 4
4

Systemic administration of anti-CD20 indirectly reduces
B cells in the inflamed meninges in a chronic model of
central nervous system autoimmunity

This chapter is based on work that is in preparation for submission:
Tesfagiorgis, Y., and S. M. Kerfoot. 2021. Systemic administration of anti-CD20
indirectly reduces B cells in the inflamed meninges in a chronic model of central
nervous system autoimmunity. In preparation.
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4.1 Introduction
Anti-CD20 B cell depleting therapies, which includes rituximab, ocrelizumab, and
ofatumumab are effective in treating patients with relapsing(1–3), and more importantly
progressive forms of multiple sclerosis (MS) (5, 6, 155). Clinical trials have demonstrated
that anti-CD20 treatment reduces the number of B cells in the cerebral spinal fluid (CSF)
(152, 155, 157, 158) and peripheral blood (3, 170). This also results in a reduction of
important measures of disease activity including a reduction in new and existing brain
lesions, clinical relapses, disability progression (1–6, 168, 170) and, importantly, T cell
accumulation in the CSF (158) and peripheral blood (157). However, because anti-CD20
therapies do not target antibody producing plasma cells, nor do they reduce antibody levels
within the therapeutic time frame (2, 157, 158), it is not clear how B cells are contributing
to disease pathogenesis.
B cells are known to accumulate in the central nervous system (CNS) of MS patients, where
they often form clusters within the meninges directly adjacent to demyelinating lesions (64,
65, 67, 68). Importantly, these clusters have been shown to correlate to early onset of
disease and severe cortical pathology (65, 67). We and others have shown that this
phenomenon is recapitulated in certain animal models of CNS autoimmunity known as
experimental autoimmune encephalomyelitis (EAE) (199, 202, 210, 217, 263). These
clusters can become more organized with separate T cell zones and B cell follicles
reminiscent of lymphoid tissue (25, 64). However more frequently they are disorganized
mixtures of B and T cells. It has been hypothesized that B cell clusters may be a local
environment within the CNS where B cells can promote disease. Nevertheless, it remains
unclear whether not these meningeal cluster B cells contribute to disease pathogenesis or
if they are susceptible to therapeutic depletion.
B cells play multiple roles in MS and EAE, complicating the analysis of B cell depleting
therapies. Work by ourselves and others suggests that, depending on the stage of disease,
both autoimmune and non-specific B cells contribute different mechanisms. For instance,
in a peptide induced model of EAE, depletion of all B cells, including non-specific cells,
prior to disease induction results in more severe disease (162, 195). This was attributed to
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IL-10 production, demonstrating that some B cells can play a regulatory role. In contrast,
anti-myelin B cells contribute to disease initiation in models that incorporate B cells in the
autoimmune response. This includes 2D2 IgHMOG spontaneous EAE (sEAE) (215, 216)
and models induced by larger protein (195, 264, 265). Nevertheless, when analyzing the
anti-myelin response to mouse MOG1-125 our lab has shown that the B cell anti-myelin
response is short-lived, and that anti-myelin B cells largely disappear (244), and do not
accumulate in B cell clusters in the inflamed spinal cord (243). Therefore, the role of antimyelin-specific B cells may be confined to the initiation of the disease, and B cell
contributions from the chronic phase likely comes from another population; including those
that accumulate in the CNS.
I set out to determine whether meningeal B cell aggregates are susceptible to depletion by
anti-mCD20 treatment. I specifically investigated the chronic phase of disease, after the
establishment of B and T cell inflammation in the CNS, to isolate the contribution of
meningeal B cells from the role of anti-myelin B cells in disease initiation. Further,
knowing that these cells have the potential to play both protective and pathogenic roles in
disease, I wanted to determine if there is an effect on disease outcome. To address these
questions, I employed the 2D2 IgHMOG sEAE model which our lab has shown results in a
chronic disease course with consistent and robust B cell accumulation in the spinal cord
adjacent to demyelinating lesions that correlate to disease severity (217). I found that
systemic administration of anti-mCD20 does not target B cells in meningeal clusters
directly, but does reduce their numbers over time, likely due to their ongoing turnover and
the elimination of peripheral B cells. Further, I found this corresponds to reduced
demyelination in the adjacent lesion. Finally, and unexpectedly, B cell depletion also
corresponded to an increase in T cells specifically in the meninges, but not white matter.
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4.2 Results
4.2.1 CNS-infiltrating B cells are reduced 7d post i.v. treatment with
anti-mCD20.
To determine the optimal dose of anti-mCD20 administration that effectively depletes B
cells in our model, I administered either 150g or 250g of anti-mCD20 (5D2), based on
previously published studies (264, 266, 267), into wild type mice i.v. and analyzed B cells
numbers in the blood, peripheral lymph nodes and spleen by flow cytometry 1d post
treatment. As expected, B cells were almost entirely depleted in the blood (Fig 4.1A),
demonstrating that depletion of B cells in the circulation is rapid and effective. B cell
numbers in the peripheral lymph nodes (axial, brachial and inguinal), and the spleen were
also reduced, but not to the same degree as observed in the blood. This suggests that antimCD20 that is administered i.v. has limited access to B cells in tissues compared to cells
in the circulation, consistent with previous analysis of i.p. administered anti-mCD20 (195)
As no difference was observed between the two doses, all subsequent experiments used
150g as the treatment dose.
To determine if systemic depletion of B cells also reduces the number of B cells in the
inflamed spinal cord in sEAE, I administered anti-mCD20 i.v. during the chronic phase of
disease (~2wks post onset, [Fig 4.1B]) then waited either 2-or 7-days post treatment to
determine the extent of B cell depletion. Isotype-control treated mice were sacrificed 2days post treatment to represent the average size of B cell clusters. Data on the disease
duration, severity, and sex of experimental mice can be found in Table 2, with no
significant difference between the days post onset for each group. By this timepoint, we
have shown that B cell meningeal clusters and T cell infiltration of the parenchyma is well
established, and that there is evidence of ongoing inflammation and demyelination (217).
I then analyzed B cell numbers in the blood, peripheral lymph nodes, spleen and spinal
cord by flow cytometry 2- or 7-days following anti-mCD20 administration. As expected,
based on the above pilot studies, B cells in the circulating blood were almost undetectable
2d post administration and remained absent 7d post treatment with a 99% reduction by 7d
post treatment, signifying that B cells were not replaced by hematopoiesis by this time
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point (Fig 4.1C). No decrease in CD4 or CD8 T cells were observed, as expected (data not
shown). B cells were also significantly reduced in lymphoid tissue (lymph nodes and
spleen) 2d and 7d post anti-mCD20-treatment compared to isotype-treated mice, but to a
lesser extent than the circulation (76% and 88% reduction respectively [Fig 4.1C]). In
contrast, there was little indication of a reduction in B cells in the inflamed spinal cord by
2d post treatment and it was not until 7d post treatment that a significant reduction of B
cells was observed (69% reduction), both as a percentage of live cells and absolute number
of B cells. This delay in the depletion of B cells in the inflamed CNS could be because it
takes longer for the Ab to cross the BBB, or it could be because there is ongoing turnover
of the CNS B cell population, and the elimination of circulating cells prevents the
recruitment of replacement B cells to the inflamed CNS.

Table 2 | Phenotype of mice treated in flow cytometry experiments.

Isotype
Control

d2 5D2 Rx

d7 5D2 Rx

Average

STDEV

age of onset

29.89

3.14

days post onset

15.11

5.95

max score

15.67

0.71

end score

14.33

1.66

female (%)

55.56

age of onset

28.44

2.88

days post onset

14.44

5.90

max score

14.89

1.27

end score

12.67

2.24

female (%)

55.56

age of onset

32.67

1.86

days post onset

17.83

5.95

max score

14.83

1.33

end score

11.67

3.20

female (%)

33.33

n

9

9

6

71
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Figure 4.1 | Depletion of meningeal B cells by systemically administered anti-mCD20 is
delayed compared to other tissues.
(A) Wild type mice were administered saline or either 150g or 250g of anti-mCD20
(5D2) i.v. 1d post injection, blood, lymph nodes (axial, brachial and inguinal), and the
spleen were harvested, for flow cytometry analysis of B cell numbers. (B) 2D2 IgHMOG
sEAE mice in the chronic phase of disease were treated with anti-mCD20 antibodies or
isotype control. Tissue was harvested 2d or 7d later for analysis by flow cytometry. (C)
Data is represented as percentage of live cells or absolute number of cells, as indicated.
Each symbol represents and individual mouse. Datasets were analyzed using one-way
ANOVA followed by a t test with Bonferroni correction. *p <0.05 and **** p <0.0001.
Mouse was created using BioRender.com.
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4.2.2 Anti-mCD20 administration reduces the number of B cells in the
meninges and this corresponds with less demyelination.
Because meningeal B cell clusters correlate with disease severity in MS (65, 67) and EAE
(210, 217), I performed additional experiments to determine if systemic B cell depletion
also reduces B cell accumulation in the meninges as well as spinal cord pathology in
chronic sEAE. sEAE mice in the chronic phase of disease were administered anti-mCD20
i.v. and spinal cords were harvested 7d later for histological analysis (see Table 3 for
disease parameters). Initial analysis revealed no differences in any measured parameters
between isotype control treated mice and untreated mice, and therefore both were included
in the control group.
As we observed previously (217), clusters of B cells were evident in the spinal cord
meninges of sEAE mice, and these clusters typically formed adjacent to regions of T cell
infiltration into the spinal cord white matter and regions of demyelination (Fig 4.2A).
Consistent with the reduction in CNS B cells observed by flow cytometry (Fig 1C) above,
the number of meningeal B cells appear to be reduced following anti-mCD20 treatment
compared to untreated controls (Fig 4.2B). This was particularly evident when looking at
the density of B cells within meningeal clusters (Fig 4.2C). Interestingly, the area of the
clusters themselves did not change over this time period (Fig 4.2D). Importantly, the area
of demyelination in the white matter was significantly reduced in treated mice (Fig 4.2E
and F), however, this did not translate to a significant difference in disease score in this 7d
timeframe (Fig 4.2G), consistent with recent observations by others (268). Nevertheless,
these observations suggest that meningeal B cells contribute to local tissue pathology.
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Table 3 | Phenotype of mice treated in immunofluorescence experiments.
Average
age of onset

Control

29.25

3.105295

days post onset

17.5

4.14

max score

15.3

0.71

end score

13.8

1.75

female (%)

d7 5D2
Rx

STDEV

8

50

age of onset

27.8

3.63

days post onset

22.2

1.30

max score

15.2

0.84

end score

10.8

2.28

female (%)

n

40

5

75
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Figure 4.2 | Anti-mCD20 treatment reduces meningeal B cell infiltration and
demyelination by 7d post treatment.
(A) Representative immunofluorescence images of spinal cords from an isotype-control
treated mouse (left) and d7 anti-mCD20 treated mouse (right) showing a large B cell cluster
adjacent to a region of demyelination. Using ImageJ, (B) the number of meningeal B cell

infiltrates and (C) density of B cells/m2 in meningeal clusters was determined from
multiple sections from each mouse. (D) Total cluster area, defined by the presence of
meningeal B and T cells, was determined in m2. (E) The extent of demyelination was
evaluated by measuring regions identified as myelin basic protein (MBP) negative and glial
fibrillary acidic protein (GFAP) positive expressed as a percentage of total spinal cord area.
Each symbol represents an individual mouse. (F) Representative immunofluorescence
images of spinal cord demyelination from control and d7 anti-mCD20 treated mice is
shown. (G) Disease curves of control and anti-mCD20 treated mice used in the histological
analysis above was tracked (left), along with the relative change in disease score over the
final 7d prior to sacrificing (right). Data is shown as mean +/- SEM. Datasets were
analyzed using a Student’s t test, *p <0.05 and **p <0.01.
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4.2.4 Reductions in meningeal B cells are not likely the result of direct
anti-mCD20-mediated depletion.
In the above experiments I established that depletion of B cells in the spinal cord following
systemic administration of anti-mCD20 is delayed relative to that observed in the
circulation and lymphatic tissues (Fig 4.1C). To determine if i.v. administered anti-mCD20
has differential access to B cells in the inflamed spinal cord compared to B cells in the
circulating blood and lymphatic tissue, I used flow cytometry to identify B cells bound by
anti-mCD20 2 or 7d post treatment. Of the very few detectable B220+ CD19+ B cells
remaining in the circulation 2d post treatment, approximately half were bound by antimCD20 (Fig 4.3A). This suggests that B cells bound by anti-mCD20 are rapidly eliminated
in the blood, perhaps as they rejoin the circulation from peripheral tissues. In lymphoid
tissue (spleen and lymph nodes), where measurable numbers of B cells were still evident,
the large majority of B cells were bound by anti-mCD20 by d2 and remained so at d7. This
may indicate that anti-mCD20-mediate depletion within tissues is slower than it is the
blood. In contrast, almost none of the B cells in the spinal cord were bound by anti-mCD20
2d after i.v. administration. This increased to ~10% of CNS B cells 7d post administration,
suggesting that the drug may not be able to cross the blood brain barrier to label cells
already in the tissue, or at least that access to the CNS is much slower than other tissues.
In order to differentiate between these possibilities, I performed a separate experiment to
look by histology for direct evidence of B cells bound by anti-mCD20 in the meninges,
and also to determine the pattern of binding within meningeal clusters. If systemically
administered anti-mCD20 does cross the blood brain barrier by 7d post administration to
directly bind B cells in meningeal clusters, we would expect to see all or most B cells in a
given cluster to be evenly bound by drug. This is not what we observed, however. Instead,
anti-mCD20-bound B cells were most commonly observed in meningeal clusters as
individual, brightly stained cells distributed among unlabeled cells (Fig 4.3B, left), and it
was common to find anti-mCD20 bound B cells immediately adjacent to unlabeled cells
(Fig 4.3B, right). This pattern is more consistent with B cells being heavily labelled in the
circulation and then carrying the drug with them as they are recruited to the cluster, rather
than the Ab crossing the BBB and labelling cells for depletion directly in the tissue.
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Figure 4.3 | Meningeal B cell depletion is indirect and is likely the result of eliminating
circulating B cells.
The blood, peripheral lymph nodes (axial, brachial and inguinal), spleen and spinal cord
were harvested from 2D2 IgHMOG mice during the chronic phase of disease after isotype or
anti-mCD20 (5D2) treatment. (A) Cells were prepared and analyzed by flow cytometry
with anti-IgG2a, a secondary antibody, to determine if B cells (CD45R+ CD19+ CD138CD4- CD8-) were bound by i.v. injected anti-mCD20. Each symbol represents an individual
mouse. Datasets were analyzed using one-way ANOVA followed by a t test with
Bonferroni correction, *p <0.05, **p <0.01 and **** p <0.0001. (B) Representative
immunofluorescence images of spinal cord meningeal B cell clusters from d7 anti-mCD20
treated mice reveal anti-mCD20 binding of meningeal B cells is not evenly distributed
(left), and B cell bound by anti-mCD20 are adjacent to unlabeled cells (right).
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4.2.5 T cells accumulate in the meninges following anti-mCD20
depletion of B cells.
Interestingly, despite a significant reduction in the number of B cells, meningeal cluster
size remained comparable between control and anti-mCD20-treated mice (Fig 4.2B, right).
Further analysis by histology revealed an accumulation of CD4+ T cells in meningeal
clusters in d7 anti-mCD20 treated mice (Fig 4.4A, bottom) compared to isotype control
treated mice (top). Indeed, the absolute number of CD4+ T cells in the meninges
significantly increased, as did the corresponding density of CD4+ T cells within clusters
(Fig 4.4B and C). Overall, this resulted in a significant shift in the dominant cell type within
clusters from B cells to T cells (Fig 4.4D). This increase in the number of CD4+ T cells
was not due to proliferation, as there was no difference in Ki67 expression as measured by
microscopy (Fig 4.4E) or flow cytometry (data not shown). There was no difference in the
number of parenchymal CD4+ T cells by d7 post treatment, indicating that they are not
likely to be leaving the parenchyma to populate the meninges (Fig 4.4F). These findings
suggest that meningeal B cells may be reactivating newly recruited CD4+ T cells to enter
the lesion. However, preliminary analysis failed to show a difference in the expression of
IL-10, IFN, or IL-17 by CD4+ T cells in the inflamed spinal cord observed by flow
cytometry (Fig 4.4G), indicating that at this time point the reduction in meningeal B cells
may not appear to measurably alter T cell phenotype.
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Figure 4.4 | T cell infiltration of the meninges increases following B cell depletion.
(A) A representative immunofluorescence image of a spinal cord from an isotype-control
treated mouse (top) and a d7 anti-mCD20 (5D2) depleted mouse (bottom) showing a
change in the dominant meningeal infiltrates from B cells to T cells. CD4+ and CD45R+
cells in the meninges were counted and the area of meningeal cluster was measured to
determine the number (B) and density (C) of T cells in clusters, and to calculate the ratio
between B cells and T cells in the meninges (D). Separate sections were stained with Ki67
and CD4 to determine the percentage of CD4+ T cells in cell cycle (E). CD4+ T cells in the
spinal cord parenchyma were counted (F). In a separate repeat experiment, peripheral
lymph nodes (left) and the spinal cord (right) were harvested for analysis of intracellular
cytokine expression using flow cytometry (G). Each symbol represents an individual
mouse. Datasets were analyzed using a Student’s t test, *p <0.05, **p <0.01.
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4.3 Discussion
Here, I characterized the effects of anti-mCD20 depletion during the chronic phase of
sEAE in 2D2 IgHMOG mice. I found that B cell depletion in the inflamed spinal cord was
delayed compared to peripheral tissues, including circulating blood, lymph nodes, and the
spleen. I attribute this delay to the mechanism of reduction of meningeal B cell numbers,
which I believe results from the ongoing turnover of the population and the removal of the
peripheral B cell pool from which it is replenished. Indeed, I did not observe evidence
consistent with the anti-mCD20 Ab crossing the BBB on its own, but rather B cells appear
to be bound by anti-CD20 in the periphery and carry the Ab with them as they are recruited
into the inflamed CNS. Indeed, previous work from our lab shows that B cells are
continuously recruited to meningeal clusters from the circulation at the chronic phase of
EAE (243). I was surprised to find that B cell depletion did not reduce the size of meningeal
clusters, which instead became dominated by T cells. I speculate that the increase in T cells
within the meninges is the result of newly recruited cells that do not go on to infiltrate the
white matter parenchyma due to the lack of B cell derived signals they normally would
receive. Interestingly, even in this short 7d timeframe a reduction in demyelination was
observed following B cell depletion.
Most studies investigating the effects of B cell depletion in models of CNS autoimmunity
to date, have focused on the initiation and acute phase of disease. Indeed, it is clear that
depending on the model, B cell depletion before or shortly after disease induction results
in less or more severe disease. For example, depleting B cells prior to disease onset in
MOG35-55 peptide induced EAE results in increased disease severity (162, 195, 267), with
reduced regulatory B10 cells observed (162). In contrast, when B cells are depleted prior
to protein induced EAE, disease severity is reduced (195, 264, 265, 267, 269). Consistent
with this finding, when B cells are depleted during the acute phase of recombinant MOG1117

EAE (4d post EAE onset), frequencies of Th1, Th17 and regulatory T cells in the

peripheral blood and CNS were decreased 14d post treatment (195), supporting a role for
B cells in the activation and differentiation of T cells. Nevertheless, it is unclear where
these effects are occurring as the immune response is initiated in the periphery and
depletion was targeted before established B cell infiltration in the CNS occurs. When
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analyzing the long-term effects of anti-CD20 treatment in the peripheral blood of MS
patients, proinflammatory Th1 and Th17 responses are reduced (227), indicating that T cell
activation is altered by B cells.
The role of meningeal B cells in the chronic phase of EAE is not well characterized. In a
very recent study investigating the chronic phase (30d post EAE onset) of MP4 protein
induced EAE, B cell depletion similarly resulted in reduced demyelination, with the
additional observation of reduced axonal damage. Interestingly, they also found a
significant increase in remyelination when mice were treated with Obinutuzumab a novel
humanized type II anti-CD20 monoclonal antibody (268). However, like us, over the short
timeframe of B cell depletion no change in disease severity was observed. In people living
with MS, anti-CD20 therapies led to a reduction in clinical relapses and disability
progression (2–6), suggesting that with more time, changes in clinical disease severity in
chronic EAE may become more apparent.
When characterizing the role B cells play in human and animal models of MS, both
pathogenic and regulatory mechanisms can be identified. Peripheral B cells from MS
patients have been shown to produce increased levels of proinflammatory cytokines such
as IL-6 (159), GM-CSF (160), lymphotoxin and TNF (226), which result in enhanced
proinflammatory peripheral blood mononuclear cell responses. Nevertheless, B cells in the
peripheral blood of MS have also been shown to play regulatory roles through their
production of IL-10 by a rare B cell population (234). In fact, many animal models of CNS
autoimmunity highlight this regulatory mechanism of B cells (161, 232, 233, 270).
Interestingly, after the cessation of anti-CD20 treatment in MS patients, peripheral blood
B cells have diminished proinflammatory cytokine production (159, 160). Interestingly,
this phenomenon is only observed in peptide induced models of EAE, where B cells are
shown to play more of a regulatory role in disease pathogenesis, but not in protein induced
EAE where B cells are activated and involved in the proinflammatory responses (267).
Indeed, Duddy et al., highlight the multifaceted role B cells can play depending on the
signals they receive (271), and in turn, their activation milieus.
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The identification of meningeal inflammatory foci in both secondary progressive (64, 65,
67) and primary progressive MS (42, 43) led to the hypothesis that local compartmentalized
immune responses are propagating the pathogenic response. Meningeal lesions have been
correlated to accelerated disease severity (67), and increased axonal atrophy in the brain
and spinal cord (66, 68), suggesting they are a deleterious site of inflammation. Here, I
aimed to characterize the effects of B cell depletion during the chronic phase of sEAE in
an attempt to isolate the contribution of meningeal B cells to disease pathology. This sEAE
model was strategically chosen for the reminiscent meningeal B cell clusters that form in
addition to the chronic disease course that is experienced (217). Future studies will be
required to determine the mechanistic action of meningeal B cells to chronic CNS
pathology and to identify why T cells accumulate within the meninges following antiCD20 treatment.
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Chapter 5
5

Overall discussion and future directions

The findings in this thesis address the phenotype of meningeal B cells within the inflamed
spinal cord of an animal model of CNS autoimmunity, and determined their susceptibility
to therapeutic depletion with anti-mCD20, the murine surrogate of Rituximab. I began with
the assumption that myelin specific B cells would be the predominant constituent of
meningeal B cell clusters, contributing to the local pathogenic B cell mechanisms in the
inflamed CNS. This was based on the observations that a majority of meningeal B cell
clusters were comprised of CD27+ memory B cells (25, 66), suggesting they were
previously activated, and the description of ectopic B cell follicles, reflective of GCs (64).
Surprisingly I challenged the hypothesis that B cells behave like T cells in their recruitment
to the inflamed CNS. Instead, I discovered that unlike T cells, activated myelin-specific B
cells are excluded from the inflamed CNS. The data in Chapter 3 suggested that clusters of
meningeal B cells are activated through a non-antigen-specific pathway to participate in
the local inflammatory immune response in both mMOGtag induced EAE and 2D2 IgHMOG
sEAE (217). B cells identified in the inflamed CNS of these models, were CD38hiCD95lo
indicative of a naïve/memory B cell, yet they upregulated the expression of CD80 and
ICOSL in comparison to lymph node B cells, suggesting they are involved in antigen
presentation to T cells. Nevertheless, because they are not specific for myelin antigen, I
propose that B cells are presenting antigen to T cell via noncognate interactions with
autoimmune T cells. In Chapter 4 I reveal that meningeal B cells can be targeted for
depletion following systemic anti-mCD20 treatment, resulting in reduced CNS pathology,
supporting the pathogenic nature of these meningeal B cells. Interestingly, this coincided
with an influx of meningeal T cells, suggesting B cells may be required for the reactivation
of T cells, allowing them to enter the parenchyma and promote further damage.
In MS, memory B cells have been identified in meningeal B cell aggregates as well as in
white matter lesions of MS patients (25, 66). Typically, CD27 has been used to identify
memory B cells in humans, though there is no equivalent phenotypic marker of memory B
cells in mice. CD27 can be a marker for a cell that is activated or that has been activated in
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the past, with ~40% of B cells in the human peripheral blood of adults expressing CD27
(272). However, with the heterogeneity of human memory B cells (273) functional
contributions need to be better characterized in MS to determine if there is indeed an
enrichment for memory B cells compared to other lymphoid structures. Further
complicating the matter in mice, IgM+ memory B cells are indistinguishable from naïve
IgM+ B cells. However, subsets of previously activated B cells have been identified based
on the differential expression of CD80, CD73 and PD-L2 (274–276), therefore future
studies should be aimed at addressing the potential memory phenotype of meningeal B
cells in these models.
While the presence of meningeal B cell follicles, with GC formation in the meninges has
been proposed as a phenomenon that can occur in SPMS (64), a thorough analysis of the
literature reveals a different story. The overall majority are more frequently reminiscent of
disorganized B cell clusters (42, 43, 67–70), similar to our findings in mMOGtag induced
EAE and 2D2 IgHMOG sEAE (217). In fact, reanalyzing SPMS post-mortem tissue revealed
that these structures were characterized by having the presence of proliferating B cells
(Ki67+), a reticulum of CD35+ FDCs producing CXCL13+, as well as the presence of Ig+
plasmablasts or plasma cells. While these appearances were observed in 2 of 3 individuals
with SPMS, upon subsequent descriptions analyzing an additional 26 SPMS tissues (in
addition to the previous 3), 41% of SPMS patients contained these meningeal B cell
follicles (12/29 cases) (65). However, yet another reinvestigation using 28 of the previously
analyzed 29 tissues, with an additional 9 more, contained 54% of SPMS tissues (20/37
cases) with features of follicle like structures (66). Yet unlike previous observations, they
lacked the presences of a GC surrounded by a mantle zone, were predominantly CD27+
memory B cells and contained CD4 and CD8 T cells, highlighting the predominate nature
of these meningeal B cell clusters to, more often than not, represent disorganized
aggregates of cells. Again, while some subsequent analyses characterize these meningeal
B cell clusters to be reminiscent of lymphoid tissue, with additional phenotypic makers
such as activation-induced cytidine deaminase, caspase-3, and Bcl-6 (63), this was an
occasional phenomenon.
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B cells in the meninges and parenchyma have been shown to be clonally related based on
variable heavy chain BCR repertoire analysis (137). Furthermore, studies looking at B cells
in the CNS show they are clonally related to B cells within cervical draining lymph nodes
(143), suggesting B cell maturation occurs outside the CNS within these structures.
Consistent with this idea is the observation that B cells from the CSF and peripheral blood
of MS patients are also clonally related (136, 144), suggesting an ongoing migration of B
cells out of the CNS, with frequent input of B cells from the periphery back into the CNS.
Indeed, meningeal lymphatic vessels are known to drain into the deep- and superficialcervical lymph nodes (277), supporting the idea that immune cells and macromolecules
can drain from the CSF into the cervical lymph nodes. This also creates an opportunity for
B cells to find relevant CNS antigens, as numerous myelin antigens have been identified
within draining cervical lymph nodes (75, 76). Nevertheless, when analyzing the
specificity of CNS resident B cells by producing recombinant human IgG from MS postmortem tissue, no candidate antigens previously implicated in MS or high-throughput
approaches were able to identify the target antigen of these B cells (146). This is consistent
with our observations in Chapter 3 that meningeal B cells clusters are not specific for
myelin antigen (243). This is supported by observations from another group that failed to
detect RFP+ MOG-specific B cells within inflammatory CNS lesions, while GFP+ MOGspecific T cells were readily observed (221). While somatic hypermutation and affinity
maturation in these clonal analyses had originally suggested B cells were undergoing an
antigen-driven immune response, the observation that memory B cells are recruited,
suggests this could just be derived from previous antigen-activation. Indeed, class-switched
IgA gut derived plasma cells specific for microbial antigens can be found in the inflamed
CNS of MOG35-55 induced EAE (233), which could explain the observation of somatically
mutated B cells within the inflamed CNS.
While the results of Chapter 4 suggest that meningeal B cells clusters are contributing to
CNS-autoimmunity, these studies do not exclude the possibility that B cells are promoting
the disease from another anatomical location in chronic EAE. However, I hypothesize that
by depleting B cells at the chronic phase of disease I was able to isolate the contribution of
meningeal B cells from the initiation role of myelin-specific B cells. This is based on
previous work from our lab that shows that the autoimmune mMOGtag GC response is
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truncated in comparison to foreign antigen GC responses, which results in the generation
of short-lived memory B cells that are not responsive to secondary stimulations (244).
Furthermore, studies looking at the effects of B cell depletion in various models of EAE
and at different time points, reveal the multifaceted role B cells play in CNS autoimmunity.
Most of these studies looked at the effects of B cell depletion prior to disease induction,
which differentiate the role of B cells during the initiation of disease (Table 4). For
example, when looking at the effects of B cell depletion prior to EAE induction using
MOG35-55, B cells appear to play a regulatory role as disease severity is exacerbated in
treated mice (162, 195, 266, 267). This finding was attributed to reduced CD1dhiCD5+
regulatory B cells (B10 cells) (162), and an influx of encephalitogenic T cells into the CNS
(195), highlight the protective role B cells play in peptide induced EAE, when they are not
activated through their BCR (194). Indeed, in peptide induced models of EAE B cells have
been shown to regulate disease severity through their production of IL-10 (161, 232, 270).
In contrast to peptide induced EAE, treatment of mice with anti-CD20 antibodies prior to
the induction of EAE using larger protein antigens such as hMOG (264, 265, 269, 278) or
MOG1-117 (195, 267) resulted in a reduction in disease severity, as well as reduced
volumetric brain volume changes (265). Overall, these finding highlight that B cell
depletion in protein induced EAE, is beneficial to clinical or pathological disease outcomes
and can be attributed to the loss of pathogenic, BCR activated, MOG-specific B cells.
While attempts were made to deplete B cells in both MOG35-55 peptide and various protein
models during the acute phase of disease, I believe that meningeal B cell cluster formation
is not fully established within the CNS by these early time points (day 1-4 post disease
onset) and therefore the effects observed were solely due to the role of peripheral B cells.
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Table 4 | The effects of B cell depletion in various models of EAE.
EAE
Model

Strain
and Sex

Rx type

C57BL/6 MB20-11
(F)
200g i.v.

MOG
35-55

hCD20

m2h7
200g i.p.

C57BL/6
200g i.p
(F)

5D2
C57BL/6
(F)
200g i.p.

hCD20

m2h7
200g i.p.

rMOG
1-117

5D2
C57BL/6
(F)
200g i.p.

Rx timepoint

Findings

Increased disease severity. More demyelination,
leukocyte infiltration, less B10 cells (CD1dhi
-7d pi
CD5+). IgM and IgG Ab response is abrogated.
Increased T effector cells in the CNS (Th1 and 17).
7d pi (no
No effect on clinical scores
symptoms)
Reduced disease severity. Saw reduced
14d pi demyelination, CD4 T cells, T effector cells, and
(symptomatic) Tregs in the CNS, with reduced T cell
proliferation.
21d pi
No effect on clinical scores
(recovery)
Increased disease severity CD11b+ APC have
-21d pi higher TNF production, reduced IL10 production
and stimulated Th1 T cell differentiation
Increased disease severity, inflammation,
demyelination, reduced CNS B cell numbers. No
12d pi, ~d2 po
change in Th1 or Th17 T cells in the CNS, a
reduction of Tregs in the CNS.
Increased disease severity. Linked to splenic
CD11b+ monocyte TNF production. Removal or
-21d pi
Tregs by anti-CD25 only modestly increased
Maintenance disease severity suggesting the reduction of Treg is
wkly
not why disease is exacerbated in anti-CD20
treated mice
Increased disease severity 6wks pi. As B cells
returned disease severity dampened. Saw enhanced
-14d, -7d, 0d pi
cellular infiltration. B cell numbers in the CNS
were restored
-21d pi Reduced disease severity
Reduced disease severity – reduced B cells in the
CNS (specifically meningeal B cells reduction).
Reduced frequency of Th1, Th17 and Treg
13d pi, ~d4 po
(CD25+, FoxP3+) 14d after Rx, and reduced antiMOG antibody titers d30 after immunization and
onwards.
Reduced disease severity 14wks post disease
induction. As B cells returned, severity worsened.
-14d, -7d, 0d pi Saw no difference in CNS infiltration or
demyelination. B cell numbers restored with an
increase in autoreactive MOG1-117 specific B cells.

Ref

(162)

(195)

(266)

(267)

(195)

(267)
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EAE
Model

Strain
and Sex

hCD20

Rx type

100g

Rx timepoint

Findings

Ref

Reduced disease severity – B cells in the
peripheral blood and spleen are reduced (13%
reduction in the CNS), reduced CD4 T cells in
the CNS. MOG-specific T cells unaltered
however, T cell proliferation to MOG1-125 is
reduced with a specific reduction in IL17 T cells
but not IFN.
Reduced disease severity – MOG specificity is
not altered but in vitro T cell proliferation to
MOG1-125 is reduced.

(264)

Reduced disease severity – Reduced anti-MOG
-7d pi IgG antibodies in the spinal cord but not the
brain or serum

(269)

3d pi
Daily Rx for
3d

20d pi (8d po)
rhMOG
1-125

hCD19
(M)
C57BL/6
(F)
C57BL/6
(F)

C57BL/6
(M)
MP4

CD20dbtg

sEAE

TCR1640
SJL/J
2D2
IgHMOG

MB2011
250g
i.p.
18B12
20mg
s.c.

-1d and d3
Reduced disease severity
pi,

100g
s.c.

-21d pi Reduced disease severity 3-4 wks pi. Rotarod
Maintenance performance improved and reduced volumetric
– wkly brain volume loss.

18B12
5mg/kg
i.v.

No effect on clinical scores:
18B12: significantly reduced axonal damage and
30, 33, and
lesion area
36d after peak
OBZ: significantly reduced axonal damage,
EAE,
lesion area, and demyelinating axons, with a
significant increase in remyelination.

OBZ
5mg/kg
i.v.
18B12
20mg
s.c.
200g
i.p.

50, 53, 56 and
59 after peak
EAE
3d after birth
Maintenance
– every 2 wks
3-4wks
preventatively

(278)

(265)

(268)

D50 Rx mice saw a significant increase in
remyelination, and a significant decrease in
demyelinating axons.
Reduced disease severity and incidence

(212)

No effect on clinical scores and incidence

(222)

Definitions: pi – post immunization, po – post onset, i.v. – intravenous, i.p. –
intraperitoneal, s.c. - subcutaneous
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Despite recent reports that subcutaneous administration of 89Zr-labeled anti-CD20 therapy
allowed for higher uptake in the CNS in comparison to i.v. administration (279), I opted to
administer the drug i.v. consistent with current methods used to treat MS patients with
ocrelizumab. Although B cell depletion in the CNS was delayed by this method, I was still
able to observe a significant reduction in meningeal B cells over time. The BBB is
selectively permeable through the presence of specialized endothelial cells with tight
junction that prevent paracellular permeability (280). During neuroinflammation that
occurs in MS, the BBB becomes leaky which I hypothesized would allow for anti-CD20
to gain access to the inflamed CNS. Immunofluorescence analysis revealed that while the
drug was apparent in the inflamed CNS, it was not restricted to certain areas but rather
observed in various meningeal clusters. This finding suggests that the drug was likely
bound to peripheral B cells and made its way into the CNS with newly recruited B cells.
Previous reports from our lab show that B cells are continuously recruited to the inflamed
CNS during EAE (243) which supports this theory. While previous attempts to deplete B
cells via intrathecal anti-CD20 treatment have been attempted in EAE, with a modest
improvement compared to i.p. administration (281), this was not effective in clinical trials
of progressive MS (282).
Meningeal B cell clusters could be contributing to CNS pathology through many effector
mechanisms such as cytokine production, as B cells have been shown to produce
proinflammatory cytokines IL-6, GM-CSF, lymphotoxin , and TNF (159, 160, 226,
227), which can influence the differentiation of T cells and myeloid cells. Furthermore, it
has been shown that B cells isolated from the peripheral blood of RRMS patients secrete
toxic factors that are not cytokines, or antibodies that induce apoptosis of neurons in vitro
(230, 231), suggesting the B cells in the inflamed CNS could also be producing these as of
yet uncharacterized toxic factors to promote tissue damage. Nevertheless, with our
observation that B cells in the inflamed CNS up regulate the expression of CD80 and are
in direct association of myelin-reactive T cells, it is likely that B cells are presenting antigen
to T cells via non-BCR-uptake mechanisms. Indeed, the work in Chapter 4 suggests that
meningeal B cells are involved in the reactivation of meningeal T cells in the inflamed
CNS, as I observed no change in the number of parenchymal, white matter T cells
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following anti-mCD20 treatment. In this study I was not able to determine why this influx
of T cells results, however this avenue of research in the future could help solidify the role
of B cells in meningeal B cell clusters. In particular, I would expect that transfer of
activated myelin specific T cells following B cell depletion during the chronic phase of
2D2 IgHMOG sEAE would result in the accumulation of myelin reactive T cells in the
meninges, while in control mice myelin specific T cells would be observed throughout the
inflamed CNS. Although no change in the cytokine profile of T cells was observed in
preliminary analysis, this finding was restricted by the analysis of total CNS infiltrating T
cells, and not just meningeal T cell phenotypes, as well as a small sample size (n=2 for
control and n=3 for anti-mCD20 treated mice). Future experiments should be completed to
characterize the cytokine profile of meningeal T cells following B cell depletion, with an
ELISA to also determine total cytokine production.
Future experiments should also be aimed at addressing the mechanism by which B cells in
the inflamed CNS may be presenting antigen to T cells. Since B cells are typically known
for endocytosing antigen through their BCR, determining whether meningeal B cells have
the capacity to take up antigen through BCR-independent pathways such as phagocytosis
will be evaluated. Peritoneal cavity B-1 cells have previously been shown to differentiate
into mononuclear phagocytes in vitro and in vivo, with the capability of phagocytosing
various antigen targets (283–285). Further supporting the capability of B cells to become
phagocytic was the observation that follicular B cells can be observed phagocytosing
antigen (286), suggesting that B cells in certain contexts and with the right stimulation can
go on to present antigen to T cells in a phagocytic-dependent manner. While I completed
a pilot sc-RNA-seq experiment to better characterize meningeal B cells, preliminary
analysis revealed that B cells within the inflamed spinal cord of 2D2 IgHMOG sEAE mice
are unique from lymph node B cells. Future experiments will be aimed at comparing
meningeal B cells to additional B cell subsets such as naïve B cells, GC B cells, memory
B cells, marginal zone B cells, and peritoneal cavity B-1 B cells in order to identify how
meningeal B cells may be contributing to disease pathogenesis.
Animal models, at their core, have many limitations in addressing human diseases, such as
the initiating events that trigger the onset of MS. Indeed, the use of mMOGtag as an
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immunogen in EAE does not contain post-translational modifications that would be found
on endogenous MOG protein in vivo making it difficult to understand the mechanisms by
which post-translational modifications affect the autoimmune response. Indeed,
extracellular MOG found on the surface of oligodendrocytes is post-translationally
modified at arginine 31 to be glycosylated, resulting in altered B cell recognition and
antibody binding (206, 287). Furthermore, inflammation in EAE tends to be localized to
the spinal cord, with a more limited spectrum of clinical signs as opposed to MS,
highlighting the limitations of these models in representing MS. Nevertheless, EAE has
played a pivotal role in allowing us to determine mechanistic insights in MS. Furthermore,
these findings are consistent with results observed by others in that myelin specific B cells
appear to be excluded from the inflamed CNS (146, 221). While I have confirmed
meningeal B cells are not specific for myelin antigen in two different models of EAE,
confirming these results in additional models such as MP4 induced EAE, a model that has
been cited to result in ectopic GC like follicles at a more frequent occurrence (210), could
help solidify this finding. Furthermore, it is unknown whether these meningeal B cell
aggregates are similar to those found in other sites of inflammation such as in spinal cord
injury, colo-rectal cancer, Sjorgen’s syndrome and systemic lupus erythematosus (288–
290) to name a few.
While the contribution of antibodies was not investigated in this thesis, their role in EAE
and MS like neurological variants of disease such as NMO and MOG-antibody disease
have been reported. Characterizing the antibody response in various EAE models revealed
that hMOG induced EAE generates pathogenic antibodies that cross-react with
glycosylated MOG and oligodendrocytes (206). These antibodies have been shown to be
pathogenic as transfer into B cell deficient mice immunized with hMOG restored
susceptibility to EAE in these otherwise resistant mice. In contrast, while rMOG still
generates a functioning antibody response, these antibodies are not able to bind
glycosylated MOG or contribute to pathology. Future experiments analyzing the antibody
response in mMOGtag induced EAE will be required to determine how the antibodies
generated in this immune response contribute to disease. Clinical trials of anti-CD20 have
confirmed that antibody levels are not affected within the therapeutic time frame (2, 157,
158), consistent with the idea that these therapies do not target antibody producing plasma
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cells as they are CD20-. Although I did not measure the antibody response following antimCD20 treatment in Chapter 4, I suspect that minimal alterations in the antibody response
would be observed based on these clinical trials. 2D2 IgHMOG mice are known to produce
large amounts of MOG-specific IgM and IgG1 antibodies regardless of whether they have
EAE onset or are asymptomatic (215), suggesting their role in disease is limited.

5.1 A model for B cell involvement in CNS autoimmunity
I hypothesize that at a minimum, two B cell populations are contributing to the
pathogenesis of CNS autoimmunity (Fig 5.1). The first population is myelin-specific B
cells that are involved in the induction of disease. Indeed, MHC class II-dependent B cell
APC function is required for hMOG induced CNS autoimmunity (165). In this model of
EAE, class switch recombination of the BCR is critical for the generation of pathogenic
autoantibodies, which have also been shown to be sufficient to restore EAE susceptibility
to hMOG in activation induced cytidine deaminase (AICD) knockout mice (207).
Likewise, another group showed that when B cells are the only cell expressing MHC class
II, that increasing the frequency of MOG-specific B cells restores susceptibility to rMOG
induced EAE (166). Consistent with this role of B cells contributing to initial APC
activation of T cells, when MHC class II is restricted to DCs alone, they are inefficient at
inducing rMOG EAE (291). Furthermore, conditional and temporal regulation of MHC
class II expression on B cells reveals MOG-specific B cells are capable of inducing an
accelerated onset of EAE in comparison to a full compartment of MHC class II APC
subsets (167). Again, while the APC function of myelin-specific B cells is clearly
supported, MOG-specific autoantibodies have also been shown to enhance antigen
presentation of resident CNS APCs, thereby enhancing the activation of incoming effector
T cells (221). Finally, sEAE occurs at an increased incidence when both MOG-specific
TCRs and BCRs are present (212, 215–217), and this has been shown to be independent of
their ability to produce antibodies (165). However, it has been reported that even in this
spontaneous model of EAE that the addition of serum from IgHMOG mice into 2D2
recipients can increase the incidence of sEAE (6/14 compared to 0/12) (222). While
autoantibodies have been shown to be involved in some variants of MS such as NMO and
MOG-antibody disorders (46, 47), this is a less common occurrence in clinically definite
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MS. Overall, these findings point towards an involvement of myelin-specific B cells in
CNS autoimmunity, potentially allowing for the activation of autoreactive T cells that can
go on to drive inflammation within the CNS.
The second population I propose is contributing to CNS autoimmunity is non-specific B
cells involved in the local CNS inflammatory responses, where I have shown that myelinspecific B cells are largely excluded (243). These meningeal B cell clusters have been
shown to correlate to disease severity in 2D2 IgHMOG sEAE (217), and following B
depletion during the chronic phase of sEAE results in a loss of meningeal B cells, and
reduced tissue pathology (Chapter 4). Consistent with our findings that myelin-specific B
cells are largely excluded from the inflamed CNS, was the identification that compared to
foreign antigen GC responses, the MOG GC response is relatively short-lived and gives
rise to fewer plasma cells relative to foreign-antigen responses (244). Instead, these antimyelin GC responses predominantly produced short-lived memory B cells, that fail to
respond to secondary challenge, suggesting that the role of myelin-specific B cells may not
extend beyond disease induction.
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Figure 5.1 | Proposed mechanism of B cell involvement in CNS autoimmunity.
Two distinct populations of B cells contribute to CNS autoimmunity. In the periphery,
myelin-specific B cells (green) can active myelin-specific T cells (red) via cognate
interactions. In turn, myelin-specific B cells acquire T cell help, producing a GC response
that can generate high-affinity, class-switched, short-lived memory B cells, and
autoantibody-secreting plasma cells. In contrast, in the CNS non-specific B cells (blue)
within the meninges promote disease pathogenesis by three probable mechanisms: 1)
reactivating myelin-specific T cells, 2) producing proinflammatory cytokines (IL6, GMCSF, TNF, and lymphotoxin), and 3) secreting soluble toxic factors. This figure was
created with BioRender.com.

96

5.2 Concluding remarks and implications to MS
The data presented in this thesis demonstrates that our current hypothesis of how B cells
contribute to disease within the inflamed CNS in anti-myelin autoimmunity is inherently
flawed. Previous assumptions were based on what we knew about CD4+ T cells, however,
it is clear that B and T cells have fundamentally different relationships within the inflamed
CNS. Furthermore, while it is still unclear how B cells contribute to the local pathology
within the inflamed CNS, the work in this thesis suggests they are involved in disease
pathogenesis. This is based on their location adjacent to demyelinating lesions, correlation
to disease severity (217), and observation that CNS pathology is reduced following their
depletion within the inflamed CNS. Although I was unable to preferentially deplete
meningeal B cells, the currently completed and future sc-RNA-seq experiments from our
lab will hopefully help identify features unique to meningeal B cells that may reveal how
to more specifically target these cells. Currently, the only approved therapy for progressive
MS is anti-CD20 B cell depleting therapies. While they have been effective at reducing
lesions within the brain, clinical relapses, and disability progression (3, 5, 6, 168), they still
result in an untargeted depletion of all CD20+ expressing B cells. By selectively targeting
the pathogenic populations of B cells in MS, this will allow for the maintenance of
regulatory B cell populations or B cells that can then go on to mount an immune response
to infections. Currently I hypothesize that standard follicular B cells recruited to the CNS
become activated within the inflammatory milieu and contribute to disease through
production of proinflammatory cytokines, neurotoxic factors, and antigen presentation to
T cells. Future work from the Kerfoot laboratory will build on these findings to characterize
meningeal B cell clusters and determine how they contribute to disease.
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Microbiology and Immunology at the University of Western Ontario in London, Ontario,
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